

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re: Application of:
Nida Abdul-Ghani Nassief**

Serial No.: 09/944,564

Filed: September 4, 2001

Group Art Unit: 1623

Examiner: Patrick T. Lewis

Our Ref.: 278455.100

**ASTHMA/ALLERGY THERAPY
THAT TARGETS T-LYMPHOCYTES
AND/OR EOSINOPHILS**

DECLARATION UNDER 37 CFR 1.132

I, David P. Skoner, residing in Pittsburgh, Pennsylvania, do declare as follows:

1. I received a Bachelor of Science degree from Juniata College, Huntingdon, PA in 1976 and an M.D. from Temple University, Philadelphia, PA in 1980.

2. I currently hold the following positions:

2005-Present: Professor of Pediatrics, Department of Pediatrics, Drexel University College of Medicine;

2003-Present: Vice Chair, Clinical Research, Department of Pediatrics, Allegheny General Hospital, Pittsburgh, PA

2003-Present: Director, Pediatric Allergy/Asthma/Immunology Allegheny General Hospital, Pittsburgh, PA.

3. I am certified by the American Board of Pediatrics and the American Board of Allergy and Immunology.

4. I serve on the following professional committees:

Editorial Board: American Journal of Rhinology (1994-1999)
Current Opinion in Allergy and Clinical Immunology (2000-Present)
Current Respiratory Medicine Reviews (2005)
Pediatric Asthma, Allergy & Immunology (2005)

Reviewer: Journal of Allergy and Clinical Immunology, Journal of Pediatrics, Journal of Laboratory and Clinical Medicine, Annals of Allergy, Journal of Infectious Diseases, American Review of Respiratory and Critical Care Medicine, International Archives of Allergy and Immunology, Annals of Otology, Rhinology & Laryngology.

5. My curriculum vitae is attached in the Appendix and further describes my professional experience and publications.

6. I was introduced to Dr. Nida Nassief when her project for the Executive Entrepreneurship Certificate Program at Carnegie Mellon's Donald H. Jones Center for Entrepreneurship, hosted by Carnegie Mellon University – Qatar Campus, was awarded first prize, and she was invited to Pittsburgh to meet specialists in our field.

7. I am familiar with the above-captioned patent application and have read the Office Action and the references cited in the office action.

8. It is my well considered opinion that the definition of asthma was well known at the time of this invention, as set forth in the NIH guidelines provided in connection with the response to the office action.

9. It is my well considered opinion that, at the time of invention, glycoprophosphopeptical would not be considered an obvious treatment for allergy or asthma. Asthma is a chronic inflammatory airways disease and is not a viral illness per se. Acute viral infections can trigger a loss of asthma control or an asthma exacerbation (as is the case with a number of other chronic illnesses), but, again, the underlying asthma is not considered a viral illness or even an infectious illness for that matter. Anti-viral

drugs are not listed as treatments for asthma in national and international guidelines. Therefore, the references cited by the Examiner would not lead one skilled in the art to select glycoposphopeptical for treatment of asthma, extrinsic or intrinsic, nor for the treatment of allergy, including perennial rhinitis, allergic conjunctivitis, chronic urticaria, atopic dermatitis or laryngeal oedema.

I am aware that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity of this application or any patent issuing thereon. All statements made herein based on my own knowledge are true and all statements made on information and belief are believed to be true.



David P. Skoner, M.D.

4/16/07

Date

APPENDIX

DAVID P. SKONER
Allegheny General Hospital

NAME: David Peter Skoner	BIRTH PLACE: Johnstown, PA
HOME ADDRESS: 10 Hillcrest Road Pittsburgh, PA 15221	BIRTH DATE: March 10, 1954
HOME PHONE: (412) 247-1926	CITIZENSHIP: United States
SOCIAL SECURITY NUMBER: Upon Request	
BUSINESS ADDRESS:	Allegheny General Hospital 320 East North Ave. Section of Allergy/Asthma/Immunology Pittsburgh, PA 15212
BUSINESS PHONE: (412) 359-6640	BUSINESS FAX: (412) 359-6641

EDUCATION AND TRAINING

UNDERGRADUATE:

1972-1976	Juniata College Huntingdon, PA	BS - 1976, Pre-Medicine
-----------	-----------------------------------	-------------------------

GRADUATE:

1976-1980	Temple University Philadelphia, PA	MD - 1980, Medicine
-----------	---------------------------------------	---------------------

POST-GRADUATE:

1980-1983	Children's Hospital Cincinnati, OH	William K. Schubert, MD General Pediatric Residency
1983-1985	Children's Hospital Pittsburgh, PA	Philip Fireman, MD Allergy/Immunology, Fellowship

EMPLOYMENT HISTORY

ACADEMIC

2005-Present	Professor of Pediatrics Department of Pediatrics Drexel University College of Medicine
2003-Present	Vice Chair, Clinical Research Department of Pediatrics Allegheny General Hospital
2003-Present	Director, Pediatric Allergy/Asthma/Immunology Allegheny General Hospital
1997-2002	Children's Hospital of Pittsburgh Chief, Section of Allergy/Immunology
1997-2002	Children's Hospital of Pittsburgh Director, Allergy and Immunology Training Program
1993-1997	Children's Hospital of Pittsburgh Associate Director Allergy and Immunology Training Program
1991-2002	Associate Professor of Pediatrics and Otolaryngology University of Pittsburgh School of Medicine Pittsburgh, PA
1986-1989	Children's Hospital Chief, Laboratory Services Division of Allergy/Immunology Pittsburgh, PA
1985-1987	Clinical Research Center Clinical Associate Physician Children's Hospital Pittsburgh, PA
1985-1988	Director, Asthma Clinic Children's Hospital Pittsburgh, PA
1985-1991	University of Pittsburgh School of Medicine Assistant Professor of Pediatrics Pittsburgh, PA

NON-ACADEMIC

February, 1998 - Present

American Academy of Allergy Asthma & Immunology
Vice Chair, Fund Interest Section Research Projects

CERTIFICATION AND LICENSURE

SPECIALTY CERTIFICATION:

1985	American Board of Pediatrics
1986	American Board of Allergy and Immunology
2001	Research Practice Fundamentals/Module 1-Research Integrity

MEDICAL LICENSURE:

1983	Pennsylvania State Board of Medical Education and Licensure - #MD-029155-E
------	---

PROFESSIONAL COMMITTEES AND ADMINISTRATIVE SERVICE

<u>Editorial Board:</u>	American Journal of Rhinology (1994-1999) Current Opinion in Allergy and Clinical Immunology (2000-Present) Current Respiratory Medicine Reviews (2005) Pediatric Asthma, Allergy & Immunology (2005)
-------------------------	--

<u>Reviewer:</u>	Journal of Allergy and Clinical Immunology, Journal of Pediatrics, Journal of Laboratory and Clinical Medicine, Annals of Allergy, Journal of Infectious Diseases, American Review of Respiratory and Critical Care Medicine, International Archives of Allergy and Immunology, Annals of Otolaryngology & Rhinology & Laryngology.
------------------	---

Committee Chairmanship:

1994-1996	Rhinitis Committee - American Academy of Allergy Asthma and Immunology
-----------	--

Committee Membership:

1989-1992	Animal Research and Care Committee, Children's Hospital
1989-1991	Clinical Laboratory Use Committee - Children's Hospital
1991-1998	Human Rights Committee, Children's Hospital
1991-Present	Resident Education Committee - Children's Hospital
1993-1994	Rhinitis Committee - American Academy of Allergy Asthma and Immunology
1994-Present	Committee to Fund Interest Section Research Projects - American Academy of Allergy and Immunology
1996-Present	Post-graduate Education Committee - Academy of Allergy and Immunology
1996-Present	Rhinitis Committee - American Academy of Allergy Asthma and Immunology

1999-2003	Grant Review Committee – American Academy of Allergy Asthma and Immunology
2002	Clinical Fellowship Award Review Committee – American Academy of Allergy, Asthma and Immunology
2003-2004	ARRD Vice Representative, Workshops Subcommittee-American Academy of Allergy Asthma and Immunology
2004 -2005	Pediatric Committee-American College of Allergy, Asthma & Immunology
2004-2005	Rhinitis/Sinusitis Committee- American College of Allergy, Asthma & Immunology
2004-2005	Rhinitis, Sinusitis & Ocular Diseases Interest Section, Workshops Representative-American Academy of Allergy Asthma and Immunology
2004-2005	RSOD Representative, Workshops Subcommittee-American Academy of Allergy Asthma and Immunology
2008-2009	Infections and Asthma Task Force, Interest Section Committee- American Academy of Allergy Asthma and Immunology

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

1985	Pittsburgh Allergy Society
1989	Pennsylvania Thoracic Society
1989	Pennsylvania Allergy Association
1989	Pittsburgh Pediatric Society
1993	Society for Pediatric Research
1993	American Academy of Allergy and Immunology
1993	American Academy of Pediatrics (Fellow; Member, Section: Allergy/Immunology)
1994	The Association for Research in Otolaryngology
1997-1999	President, Pittsburgh Allergy Society
1999	American College of Allergy, Asthma and Immunology
2000-2001	Board of Regents, PA Allergy and Asthma Association
2001	Board Member and Section Editor, <i>Current Opinion</i>
2004	Governing Board Member, Western Pennsylvania Asthma Consortium (WestPAC)
2006	American Pediatric Society

HONORS AND AWARDS

1983	Ross Award for Excellence in Ambulatory Pediatrics Children's Hospital, Cincinnati, Ohio
1984	Travel Grant - American Academy of Pediatrics
1985	Young Investigator Award for Excellence in Research Completed in Allergy and Immunology - American Academy of Allergy and Immunology
1985	Parke-Davis Award for Distinguished Achievement as a Fellow in Allergy

- and Immunology - American College of Allergists
- 1985 Geigy Fellowship Award for Excellence in Allergy and Immunology Research
- 1985 Travel Grant - Aspen Allergy Conference
- 1985 Travel Grant - International Congress of Allergology and Clinical Immunology
- 1985-87 Clinical Associate Physician Award, National Institutes of Health,
General Clinical Research Center
- 1987 Travel Grant - Aspen Allergy Conference
- 1992 Joseph E. Ghory Memorial Lectureship, Ohio Society of Allergy and Immunology
- 2002 Kingston's National Registry of Who's Who™
- 2003 "America's Top Doctors" recognition, Castle Connolly Medical Ltd.
- 2004 Nominee "2004 Health Care Hero Awards", Innovation & Research, Sponsors:
Pittsburgh Business Times, Hilton Pittsburgh, MedTech
- 2004 "America's Top Doctors" recognition, Castle Connolly Medical Ltd.
- 2005 "Top Doctors", *Pittsburgh* magazine
- 2005 "America's Top Doctors" recognition, Castle Connolly Medical Ltd.
- 2006 "America's Top Doctors" recognition, Castle Connolly Medical Ltd.
- 2007 Panel member of the Best Pharmaceuticals for Children Act (BPCA) Pediatric
Asthma Therapeutics Group convened by the National Institute of Child Health and
Human Development.
- 2007 "America's Top Doctors" recognition, Castle Connolly Medical Ltd.

PUBLICATIONS

****REFEREED ARTICLES:**

1. **Skoner DP**, Doyle WJ, Chamovitz A, Fireman P: Eustachian tube obstruction (ETO) after intranasal challenge with house dust mite. *Arch Otolaryngol* 112:840-2, 1986.
2. **Skoner DP**, Fischer T, Gormley C, Martinez R, Bobbitt R, Hollroyde J: Pediatric predictive index for hospitalization in acute asthma. *Ann Emerg Med* 16:25, 1987.
3. **Skoner D**, Doyle WJ, Fireman P: Eustachian tube obstruction (ETO) after histamine nasal provocation - A double blind dose response study. *J Allergy Clin Immunol* 79:27-31, 1987.
4. Fireman P, **Skoner DP**, Tanner EP, Doyle WJ: A primate model for the evaluation of antihistamines. *Ann Allergy* 59:9-12, 1987.
5. **Skoner DP**, Page R, Asman B, Gillen L, Fireman P: Plasma elevations of histamine and a prostaglandin metabolite in acute asthma. *Am Rev Respir Dis* 137:1009-1014, 1988.
6. Doyle WJ, McBride TP, **Skoner DP**, Maddern BR, Gwaltney JM, Uhrin M: A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. *Pediatr Infect Dis J* 7:229, 1988.
7. Page R, Friday G, Stillwagon P, **Skoner D**, Caliguiri L, Fireman P: Asthma and selective immunoglobulin subclass deficiency: Improvement of asthma after immunoglobulin replacement therapy. *J Pediatr* 112:127-131, 1988.
8. **Skoner DP**, Stillwagon PK, Casselbrandt ML, Tanner ET, Doyle WJ, Fireman P: Inflammatory mediators in chronic otitis media with effusion (OME). *Arch Otolaryngol Head Neck Surg* 114:1131-1133, 1988.
9. **Skoner DP**, Doyle WJ, Boehm S, Fireman P: Late phase eustachian tube and nasal allergic responses associated with inflammatory mediator elaboration. *Am J Rhinol* 2:155-161, 1988.

10. **Skoner DP**, Doyle WJ, Boehm S, Fireman P: Priming of the nose and eustachian tube during natural pollen exposure. *Am J Rhinol* 3(2):53-57, 1989.
11. **Skoner DP**, Fireman P, Davis H, Wall R, Caliguiri L: Increases in plasma concentrations of a prostaglandin metabolite in acute airway obstruction. *Arch Dis Child* 64:1112-1117, 1989.
12. **Skoner DP**, Gentile D, Evans R: Decreased activity of the platelet Na⁺, K⁺ adenosine triphosphatase enzyme (ATPase) in allergic subjects. *J Lab Clin Med* 115:535-40, 1990.
13. Tanner EP, **Skoner DP**, Doyle WJ, Fireman P: Intranasal challenge of cynomolgus monkeys with ascaris, ragweed, bradykinin and histamine. *Am J Rhinol* 4:33-36, 1990.
14. **Skoner DP**, Hodgson MJ, Doyle WJ: Laser printer rhinitis (refereed letter to editor). *N Engl J Med* 322:1323, 1990.
15. **Skoner DP**, Fireman P, Caliguiri L, Davis H: Plasma elevations of histamine and a prostaglandin metabolite in acute bronchiolitis. *Am Rev Respir Dis* 142:359-364, 1990.
16. Doyle WJ, Boehm S, **Skoner DP**: Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin and prostaglandin in adult volunteers with and without nasal allergy. *J Allergy Clin Immunol* 86:924-35, 1990.
17. **Skoner DP**, Lee L, Doyle WJ, Boehm S, Fireman P: Nasal physiology and inflammatory mediators during natural pollen exposure. *Ann Allergy* 65:206-210, 1990.
18. **Skoner DP**, Gentile D, Evans R: A circulating inhibitor of the platelet Na⁺,K⁺ adenosine triphosphatase (ATPase) enzyme in allergy. *J Allergy Clin Immunol* 87:476-82, 1991.
19. **Skoner DP**, Doyle WJ, Boehm S, Fireman P: Effect of terfenadine on nasal, eustachian tube and pulmonary function after provocative intranasal histamine challenge. *Ann Allergy* 67:619-624, 1991.
20. Doyle WJ, **Skoner DP**, Fireman P, Seroky JT, Green I, Ruben F, Kardatzke DR, Gwaltney JM: Rhinovirus 39 infection in allergic and non-allergic subjects. *J Allergy Clin Immunol* 89:968-78, 1992.
21. **Skoner DP**: Wiskott-Aldrich Syndrome presenting as possible allergy - unusual presentation for an unusual disease. *Pediatr Asthma Allergy and Immunol* 6(3):175-181, 1992.
22. Chande VT, **Skoner DP**: A trial of nebulized magnesium sulfate to reverse bronchospasm in asthmatic patients. *Ann Emerg Med* 21:1111-1115, 1992.
23. **Skoner DP**, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P: Effect of rhinovirus 39 (RV-39) infection on cellular immune parameters in allergic and non-allergic subjects. *J Allergy Clin Immunol* 92:732-743, 1993.
24. Igarashi Y, **Skoner DP**, Doyle WJ, White MV, Fireman P, Kaliner MA: Analysis of nasal secretions during experimental rhinovirus upper respiratory infections (URI). *J Allergy Clin Immunol* 92:722-731, 1993.
25. Gentile DA, Brown C, **Skoner DP**: In vitro modulation of platelet sodium, potassium adenosine triphosphatase (Na⁺,K⁺ ATPase) enzyme activity by anti-allergy drugs. *J Lab Clin Med* 122:85-91, 1993.
26. Doyle WJ, **Skoner DP**, Seroky J, Fireman P: Effect of experimental influenza infection on nasal response to histamine challenge in allergic and non-allergic subjects. *Am J Rhinol* 7(5):227-235, 1993.
27. Gentile D, **Skoner DP**: A circulating inhibitor of the platelet Na⁺,K⁺ adenosine triphosphatase enzyme (ATPase) in patients with allergic diseases. *Pediatr Asthma Allergy and Immunol* 7(4):217-226, 1993.
28. Doyle WJ, Tanner E, **Skoner DP**, Fireman P: Middle ear response to nasal provocation in ascaris sensitized cynomolgus monkeys. In *Recent Advances in Otitis Media*. Lim, Bluestone, Klein, Nelson Ogra (eds), Decker, pp. 330-334, 1993.
29. **Skoner DP**, Asman B, Fireman P: Effect of chlorpheniramine on airway physiology and symptoms during natural pollen exposure. *Am J Rhinol* 8(1): 43-48, 1994.
30. Doyle WJ, **Skoner DP**, Hayden F, Buchman CA, Seroky JT, Fireman P: Nasal and otologic effects of experimental influenza A virus infection. *Ann Otol Rhinol Laryngol* 103:59-69, 1994.
31. Doyle WJ, **Skoner DP**, Seroky JT, Fireman P, Gwaltney JM: Effect of experimental rhinovirus 39 infection on the nasal response to histamine and cold air challenges in allergic and non-allergic subjects. *J Allergy Clin Immunol* 93:534-542, 1994.
32. Buchman CA, Doyle WJ, **Skoner D**, Fireman P, Gwaltney JM: Otologic manifestations of experimental rhinovirus infection. *Laryngoscope* 104:1295-1299, 1994.
33. Vayonis AG, Seroky JT, Doyle WJ, **Skoner DP**, Fireman P: Intranasal histamine, methacholine and bradykinin challenge in children with and without allergy. *Amer J Rhinol* 9(1):1-7, 1995.
34. Wadowsky RM, Mietzner SM, **Skoner DP**, Doyle WJ, Fireman P: Effect of experimental influenza A virus infection on isolation of streptococcus pneumoniae and other aerobic bacteria from the oropharynges of allergic and nonallergic adult subjects. *Infect Immun* 63(4):1153-1157, 1995.

35. **Skoner DP**, Doyle WJ, Tanner EP, Kiss J, Fireman P: Effect of rhinovirus 39 (RV-39) infection on immune and inflammatory parameters in allergic and non-allergic subjects. *Clin Exper Allergy* 25:561-67, 1995.
36. Doyle WJ, **Skoner DP**, Seroky JT, Fireman P: Reproducibility of the effects of intranasal ragweed challenges in allergic subjects. *Annal Allergy Asthma Immunol* 74(2):171-176, 1995.
37. Cohen S, Doyle WJ, **Skoner DP**, Fireman P, Gwaltney JM, Newsom JT: State and trait negative affect as predictors of objective and subjective symptoms of respiratory viral infections. *J Personality Social Psychol* 68:159-169, 1995.
38. Friday GA, Bellinger MF, **Skoner DP**, Kinnunen D, Joos M, Wiltsie G, Rueter M: Latex hypersensitivity in children with spina bifida. *Pediatr Asthma Allergy and Immunol* 9(4):189-192, 1995.
39. Szeftler SJ, Bender BG, Jusko WJ, Lanier BQ, Lemanske RF, **Skoner DP**, Stempel DA: Evolving role of theophylline for treatment of chronic childhood asthma. *J Pediatr* 127(2):176-85, 1995.
40. Buchman CA, Doyle WJ, **Skoner DP**, Post JC, Alper CM, Seroky JT, Anderson K, Preston RA, Hayden F, Fireman P, Ehrlich GD: Influenza A virus-induced acute otitis media. *J Infect Dis* 172(5):1348-51, 1995.
41. Doyle WJ, **Skoner DP**, White M, Hayden F, Kaplan AP, Kaliner MA, Shibayama Y, Fireman P: Pattern of nasal secretions during experimental influenza virus infection. *Rhinology* 34:2-8, 1996. 1996.
42. Gentile DA, Braun E, **Skoner DP**: Modulation of histamine release by sodium, potassium adenosine triphosphatase enzyme inhibition. *Annal Allergy Asthma Immunol* 77 :320-326, 1996.
43. **Skoner DP**, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P: Effect of influenza A (FLU) virus infection on natural and adaptive cellular immunity. *Clin Immunol Immunopathol* 79(3):294-302, 1996.
44. Gentile DA, **Skoner DP**: A role for the sodium, potassium adenosine triphosphatase (Na⁺,K⁺ ATPase) enzyme in degranulation of rat basophilic leukemia cells. *Clin Exper Allergy* 26:1449-1460, 1996.
45. **Skoner DP**, Doyle WJ, Seroky J, Fireman P: Lower airway responses to influenza A virus in healthy allergic and non-allergic subjects. *Amer J Resp Crit Care Med* 154:661-664, 1996.
46. **Skoner DP**, Doyle WJ, Seroky J, Van Deusen MA, Fireman P: Lower airway responses to rhinovirus 39 in healthy allergic and non-allergic subjects. *Eur Respir J* 9:1402-1409, 1996.
47. Alper CM, Doyle WJ, **Skoner DP**, Buchman CA, Seroky JT, Gwaltney JM, Cohen SA: Pre-challenge antibodies moderate infection rate, and signs and symptoms in adults experimentally challenged with rhinovirus type 39. *Laryngoscope* 106:1298-1305, 1996.
48. **Skoner DP**, Angelini BL, Jones A, Seroky J, Doyle WJ, Fireman P: Suppression of in vivo cell-mediated immunity by influenza A (FLU) virus infection of adults. *Inter J Pediatr Otorhinolaryngol* 38:143-53, 1996.
49. Shibayama Y, **Skoner DP**, Suehiro S, Konishi J, Fireman P, Kaplan AP: Bradykinin levels during experimental nasal infection with rhinovirus and attenuated influenza virus. *Immunopharmacology* 33:311-313, 1996.
50. **Skoner DP**, Gentile D, Chin TW, Nussbaum E: Risk/Benefit ratio of inhaled steroids [2] (multiple letters). *Journal of Pediatrics* 129/6:942-943, 1996.
51. **Skoner DP**, Boltansky H, Kobayashi RH, Pearlman DS, Shapiro G, Harrison JE, Trochelman LM, Lorber RR: Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. *Annals of Allergy, Asthma and Immunology* 76/5:462-468, 1996.
52. Gentile DA, Katz A, Henry J, **Skoner DP**: Inhibition of peripheral blood mononuclear cell proliferation by cardiac glycosides. *Annals of Allergy and Immunol* 78:466-72, 1997.
53. Cohen S, Doyle WJ, **Skoner DP**, Rabin BS, Gwaltney JM. Social ties and susceptibility to the common cold. *JAMA* 277:1940-1944, 1997.
54. Reyes J, Todo S, Green M, Yunis E, **Skoner D**, Kocoshis S, Furukawa H, Abu-Elmagd K, Tzakis A, Bueno J, Starzl TE: Graft-versus-host disease after liver and small bowel transplantation in a child. *Transplantation* 11:345-348, 1997.
55. Gentile DA, **Skoner DP**: The relationship between airway hyperreactivity (AHR) and Na,K adenosine triphosphatase (ATPase) enzyme inhibition. *J Allergy Clin Immunol* 99:367-73, 1997.
56. Van Deusen MA, Gentile DA, **Skoner DP**: Inhibition of the sodium, potassium adenosine triphosphatase enzyme in peripheral blood mononuclear cells of allergic rhinitis subjects. *Annal Allergy Asthma Immunol* 78:259-64, 1997.
57. Angelini BA, Van Deusen MA, Doyle WJ, Seroky J, Cohen S, **Skoner DP**. Lower airway responses to rhinovirus-Hanks in healthy subjects with and without allergy. *J Allergy Clin Immunol* 99(5):618-619, 1997.
58. **Skoner DP**: Control of allergic rhinitis with antihistamines may prevent the onset or recurrence of otitis media. *Pediatric-Asthma-Allergy-Immunol* 11/4:193-205, 1997.

59. Van Deusen MA, Angelini BA, Cordoro K, Seiler BA, Wood L, **Skoner DP**. Efficacy and safety of oral immunotherapy with short ragweed extract. *Ann Allergy Asthma Immunol.* 78:573-580, 1997.
60. Yuta A, Doyle WJ, Gaumond E, Ali M, Tamarkin L, Baraniuk JN, Van Deusen M, Cohen S, **Skoner DP**. Rhinovirus infection induces mucous hypersecretion, *Am J Physiol* 274:L1017-23, 1998.
61. Gentile DA, Doyle W, Whiteside T, Fireman P, Hayden FG, Doyle W, **Skoner DP**. Increased interleukin-6 levels in nasal lavages following experimental influenza A viral infection *Clin Diag Lab Immunolo* 5:604- 608, 1998.
62. **Skoner DP**: Otitis Media and Rhinitis in Children. *Respiratory Care*, MRC3024, April 1998.
63. Alper CM, Doyle JW, **Skoner DP**, Buchman CA, Cohen S, Gwaltney JM: Prechallenge Antibodies Moderate Disease Expression in Adults Experimentally Exposed to Rhinovirus Strain Hanks. *Clinical Infectious Diseases* 27:119-128, 1998
64. Cohen S, Frank E, Doyle JW, **Skoner DP**, Rabin BS, Gwaltney Jr., JM: Types of Stressors That Increase Susceptibility to the Common Cold in Healthy Adults. *Health Psychology*, 17(3):214-223, 1998 .
65. Doyle WJ, **Skoner DP**, Patel A, Hayden FG. Effect of rimantadine on induced specific serum haemagglutination-inhibiting antibody and nasal IgA titres after experimental exposure of adults to influenza A virus. *Antiviral Therapy* 3:19-23, 1998.
66. Doyle WJ, **Skoner DP**, Alper CM, Allen G, Moody SA, Seroky JT, Hayden FG: Effect of Rimantadine Treatment on Clinical Manifestations and Otolological Complications in Adults Experimentally Infected with Influenza A (H1N1) Virus. *Journal of Infect Dis*,177:1260-5, 1998.
67. Dykewicz MS, et al, **Skoner DP**. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. *American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol.* 1998 Nov;81(5 Pt 2):478-518.
68. Dykewicz, MS, et al, **Skoner DP**. Joint Task Force summary statements on Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol.* 1998;81(5 Pt 2):474-7.
69. Cohen S, Doyle JW, **Skoner DP**: Psychological Stress, Cytokine Production, and Severity of Upper Respiratory Illness. *Psychosomatic Medicine* 61:175-180, 1999.
70. **Skoner DP**, Gentile DA, Patel A, Doyle JW: Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. *The Journal of Infectious Diseases* 180:10-14, 1999
71. Gentile DA, Patel A, Ollia C, Fireman P, Zeevi A, Doyle JW, **Skoner DP**: Diminished IL-10 production in subjects with allergy after infection with influenza A virus. *J Allergy Clin Immunol* 1999;103:1045-8.
72. Miller GE, Cohen S, Rabin BS, **Skoner DP**, Doyle JW: Personality and Tonic Cardiovascular, Neuroendocrine and Immune Parameters. *Brain, Behavior, and Immunity* 13:109-123, 1999
73. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, Galant SP, Grossman J, Hampel FC, Ratner PH, Ruff ME, Schenkel EJ, Segal AT, Segal N, Stewart GE, Tripathy I, **Skoner DP**, Anolik R, Dockhorn RJ, van Bavel J, Mesarina-Wicki B, Nolop KB, Doyle WJ. Dose-ranging study of mometasone fuorate aqueous nasal spray (Nasonex) in children with seasonal allergic rhinitis. *J Allergy Clin Immunol* 1999;104:107-14.
74. Feldman PJ, **Skoner DP**, The impact of personality on the reporting of unfounded symptoms and illness. *J Pers Soc Psychol.* 77(2):370-8, 1999.
75. Doyle WJ, Alper CM, Buchman CA, Moody SA, **Skoner DP**, Cohen S. Illness and otological changes during upper respiratory virus infection. *Laryngoscope* 1999;109:324-8.
76. **Skoner D**, Angelini B, Friday G, Gentile D. Clinical use of nebulized budesonide inhalation suspension in an asthmatic child. *J Allergy Clin Immunol.* 1999;104:S210-4.
77. Scott MB, **Skoner DP**. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. *J Allergy Clin Immunol* 1999;104:200-9.
78. Kemp JP, **Skoner DP**, Szeffler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. *Ann Allergy Asthma Immunol.* 1999;83:231-9.
79. **Skoner DP**, et al. Inhaled corticosteroids in children: optimizing the benefits, understanding the risks. *J Respir Dis.* 1999;Vol 20: S1-S40.
80. **Skoner DP**, Szeffler SJ, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. *J Allergy Clin Immunol* 2000;105:259-68.
81. **Skoner DP**. Complications of allergic rhinitis. *J Allergy Clin Immunol* 2000;105:605-9.

82. Schenkel EJ, **Skoner DP**, Bronsky EA, Miller D, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vanderwalker ML, Wanderer A, Damaraju CV, Nolop KB, Messarina-Wicki, B. Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. *Pediatrics*, 2000;105:E22.
83. **Skoner DP**, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. *Pediatrics*, 2000;105:E23.
84. Doyle WD, Seroky JT, Angelini BL, Gulhan M, **Skoner DP**, Fireman P. Abnormal Middle Ear Pressures During Experimental Influenza A Virus Infection - Role of Eustachian Tube Function Auris Nasus Larynx 2000; 27(4):323-326.
85. **Skoner DP**. Pharmacokinetics, pharmacodynamics, and the delivery of pediatric bronchodilator therapy. *J Allergy Clin Immunology* 2000; 106(3) S158-64.
86. Sheikh, S, Null D, Gentile D, Bimle C, **Skoner D**, McCoy K, Guthrie R. Urinary leukotriene E4 excretion during the first month of life and subsequent bronchopulmonary dysplasia in premature infants. *Chest*, 2001;119(6): 1749-54.
87. Gentile DA, Yokitis J, Angelini BL, Doyle WJ, **Skoner DP**. Effect of intranasal challenge with interleukin-6 on upper airway symptomatology and physiology in allergic and non-allergic subjects. *Annals Allergy, Asthma Immunol* 2001; 86(5): 531-6.
88. Milgrom H, **Skoner DP**, Bensch G, Kim K, Claus R, Baumgartner R. Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. *J Allergy Clin Immunol* 2001;108:938-45.
89. Gentile D, Doyle W, Fireman P, **Skoner DP**. Effect of experimental influenza A infection on systemic immune and inflammatory parameters in allergic and nonallergic adult subjects. *Ann Allergy Asthma Immunol* 2001; 87:496-500.
90. **Skoner DP**, Gentile DA, Fireman P, Cordero K, Doyle WJ. Urinary histamine metabolite elevations during experimental influenza A infection. *Annals Allergy, Asthma and Immunol* 2001; 87:303-306.
91. Buchman C, Doyle W, Pilcher O, Gentile D, **Skoner D**. Nasal and otological effects of experimental respiratory syncytial virus infection in adults. *Am J Otolaryngol* 2002; 23:70-75.
92. Gentile DA, Doyle WJ, Belenky S, Ranck H, Angelini B, **Skoner DP**. Nasal and oral nitric oxide levels during experimental RSV infection of adults. *Acta Oto-Laryngol* 2002; 122:61-66.
93. **Skoner DP**, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetate and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. *Ann Allergy Asthma Immunol* 2003; 90:56-62.
94. Gentile D, **Skoner DP**. Effect of respiratory syncytial virus infection during early infancy on the ontogeny of cytokine immune responses. *Allergy & Asthma Proc* 2002; 23 (6):399-405.
95. Bisgaard H, **Skoner DP**. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. *AJRCCM* 2003; 167:379-383.
96. Cohen S, Doyle WJ, Turner RB, Alper CM, **Skoner DP**. Emotional style and susceptibility to the common cold. *Psychosom Med* 2003; 65 (94):652-657.
97. Gentile DA, Doyle WJ, Zeevi A, Piltcher O, **Skoner DP**. Cytokine gene polymorphisms moderate responses to respiratory syncytial virus in adults. *Human Immunology* 2003; 64:93-98.
98. Krahne J, Gentile DA, Cordero K, Angelini BA, Cohen SA, Doyle WJ, **Skoner DP**. Comparison of subject-reported allergy versus skin test results in a common cold trial. *Am J of Rhinol* 2003;17:159-162.
99. Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Kapadia S, Trecki J, **Skoner DP**. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. *Human Immunol*, 2003; 64:338-344.
100. Gentile DA, Fireman P, **Skoner DP**. Elevations of local leukotriene C₄ levels during viral upper respiratory tract infections. *Ann Allergy Asthma Immunol*. 2003; 91:270-274.
101. Gentile DA, Villalobos E, Angelini B, **Skoner D**. Cytokine levels during symptomatic viral upper respiratory tract infection. *Ann Allergy Asthma Immunol* 2003; 91(4):362-367.
102. Cohen S, Doyle WJ, Turner R, Alper CM, **Skoner DP**. Sociability and susceptibility to the common cold. *Psychol Science* 2003; 14 (5):389-395.
103. Gentile , Howe-Adams J, Trecki J, Patel A, Angelini B, **Skoner D**. Association between environmental tobacco smoke and diminished dendritic cell interleukin 10 production during infancy. *Ann Allergy Asthma*

- Immunol 2004; 92:433-437.
104. Gentile DA, Schreiber R, Howe-Adams J, Trecki J, Patel A, Angelini B, **Skoner DP**. Diminished dendritic cell (DC) IL-10 production in atopic children. *Ann Allergy Asthma Immunol* 2004; 92:538-544.
 105. Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Trecki J, **Skoner DP**. Association between TNF- α and TGF- β genotypes in infants and parental history of allergic rhinitis and asthma. *Human Immunol* 2004; 65(4):347-351.
 106. Cohen S, Doyle WJ, Turner RB, Alper CM, **Skoner DP**. Childhood socioeconomic status and host resistance to infectious illness in adulthood. *Psychosom Med* 2004; 66 (4):553-558.
 107. Krahnke J, Gentile D, Angelini B, Danzig M, **Skoner D**. Comparison of objective and subjective measurements of cough frequency in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2004;93(3):259-264.
 108. Gentile DA, Howe-Adams J, Trecki J, Patel A, Angelini B, **Skoner DP**. Diminished dendritic cell IL-10 production during infancy. *Ped Asthma Allergy & Immunol* 2004;17 (4):278-286.
 109. Polk DE, Cohen S, Doyle WJ, **Skoner DP**, Kirschbaum C. State and trait affect as predictors of salivary cortisol in healthy adults. *Psychoneuroendocrinology* 2005; 30 (3):261-272.
 110. Skoner DP, Greos LS, Kim KT, et al. Evaluation of the safety and efficacy of levalbuterol in two-to five-year-old patients with asthma. *Pediatr Pulmonol* 2005;40(6):477-486.
 111. Gentile D, Trecki J, Patel A, Fausnight T, Angelini B, **Skoner DP**. Effect of Tetanus Immunization on T Helper (Th) Cytokine Production in Adults With and Without Allergic Rhinitis. *Allergy and Asthma Proceedings* 2006;27:197-201.
 112. Berger W, Milgrom H, **Skoner DP** et al. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo-and active-controlled trial. *Current Medical Research and Opinions* 2006;22(6):1217-1226.
 113. Skoner DP, Gentile DA, Angelini B, Doyle WJ. Allergy skin test responses during experimental infection with respiratory syncytial virus. *Ann Allergy Asthma Immunol* 2006;96:834-839.
 114. Speer EM, Gentile DA, Zeevi A, Pillage G, Huo D, **Skoner DP**. Role of single nucleotide polymorphisms of cytokine genes in spontaneous preterm delivery. *Human Immunology* 2006; 67:915-923.
 115. Gentile D, Trecki J, Patel A, Fausnight T, Angelini B, **Skoner D**. Effect of tetanus immunization on t-helper cytokine production in adults with and without allergic rhinitis. *Allergy Asthma Proc* 2006; 27:197-201.
 116. Senol M, Ozerol IH, Patel AV, **Skoner DP**. The effect of Na⁺-K⁺ ATPase inhibition by ouabain on histamine release from human cutaneous mast cells. *Mol Cell Biochem* 2007; 294:25-29.
 117. **Skoner DP**. Wheeze in preschool children: therapeutic challenges with controller medications. *Consultant for Pediatricians* 2007; 6 (4): 205-214.
 118. Skoner DP, Maspero JF. Assessment of long-term safety of inhaled ciclesonide on growth in children with asthma. *Pediatrics* 2008; 121(1):e1-e14.

REVIEWS, BOOKS AND BOOK CHAPTERS:

1. **Skoner D**, Stillwagon P, Friedman R, Fireman P: Pediatric Allergy and Immunology. In *Atlas of Pediatric Physical Diagnosis*. H. Davis and B. Zitelli (eds), Gower Press, First Edition, 1987.
2. **Skoner DP**, Caliguiri L: The Wheezing Infant. In *Pediatric Allergic Disease*. P. Fireman (ed), W.B. Saunders. *Ped Clinics N America*, 35(5):1011-1030, 1988.
3. **Skoner DP**, Doyle WJ, Fireman P: Intranasal challenge with histamine and saline: Effects on tubal and nasal function. In *Proceedings of the 4th International Symposium on Recent Advances in Otitis Media*. Lim, Bluestone, Klein, Nelson (Eds.), B.C. Decker Inc., pp. 67-69, 1988.
4. **Skoner DP**, Doyle WJ, Boehm S, Fireman P: Patterns of response of the nose and eustachian tube to provocative allergen challenge. In *Proceedings of the 4th International Symposium on Recent Advances in Otitis Media*. Lim, Bluestone, Klein, Nelson (Eds.), B.C. Decker Inc., pp. 96-102, 1988.
5. **Skoner DP**: Asthma update - A new focus for an old disease, In *Masters in Allergy*. P. Fireman (ed), Cliggott Publishing Co., 1990.
6. Friday G, Kumer S, **Skoner D**, Fireman P. Asthma and selective immunoglobulin subclass deficiency: Further results of intravenous gamma globulin replacement therapy. In *Advances in Asthma 1990, Proc XIIIth World Congress of Asthmology, Excerpta Medica*, (eds S. Kobayashi and J. Bellanti, pp 237-242.
7. **Skoner DP**: Asthma, In *Atlas of Allergies*. P. Fireman and R. Slavin (eds), Gower Press, 1991.
8. **Skoner D**, Urbach AH, Fireman P: Pediatric Allergy and Immunology. In *Atlas of Pediatric Physical Diagnosis*.

- H. Davis and B. Zitelli (eds), Gower Press, Second Edition, 1992.
9. Karol M, Griffiths-Johnson DA, **Skoner DP**: Chemically-induced pulmonary hypersensitivity, airway hyperreactivity and asthma; In Toxicology of the Lung (2nd ed.). D. Gardner, J. Crapo, R. McClellan (eds.), Raven Press, New York, 1993.
10. Doyle WJ, Tanner E, **Skoner DP**, Fireman P: Middle ear response to nasal provocation in ascaris sensitized cynomolgus monkeys. In Proceedings of 5th International Congress of Otitis Media, 1992.
11. **Skoner DP** (Guest Editor): Breathing Free, Patient Education Newsletter, published by Rhone-Poulenc Rorer Pharmaceuticals Inc., 1994.
12. **Skoner DP**, Casselbrant M: Diseases of the Ear. In Allergy, Asthma, and Immunology From Infancy to Adulthood (3rd edition). Bierman CW, Pearlman DS, Shapiro GG, Busse WW (eds), W. B. Saunders Company, 1996.
13. **Skoner DP**: Asthma, In Atlas of Allergies. P. Fireman and R. Slavin (eds), Gower Press, Second Edition, 1996.
14. **Skoner D**, Urbach AH, Fireman P: Pediatric Allergy and Immunology. In: Atlas of Pediatric Physical Diagnosis. H. Davis and B. Zitelli (eds), Gower Press, Third Edition, 1997.
15. Post JC, Aul JJ, White GJ, Wadowsky RD, Doyle WJ, Fireman P, **Skoner DP**, Buchman CA, Ehrlich GD: PCR detection of Streptococcus pneumonia, Hemophilus influenza and Moraxella catarrhalis via a multiple assay following Influenza A virus challenge of the human nasopharynx. In: Lim DJ, Bluestone CD, Casselbrant ML, Klein JO, Ogra PL (eds), Proceedings of the Sixth International Symposium on Recent Advances in Otitis Media. Toronto: B.C. Decker, Inc., 1996:421-422
16. Doyle WJ, **Skoner DP**, Alper CM, Allen G, Moody SA, Seroky JT, Hayden FG: Effect of Rimantadine Treatment on Clinical Manifestations and Otolological Complications in Adults Experimentally Infected with Influenza A (H1N1) Virus.
17. **Skoner DP**, Howrie D. Viral Respiratory Infections. Conn's Current Therapy. Saunders 1999. 217-219.
18. Gentile DA, Friday G, **Skoner DP**. Management of Rhinitis: antihistamines and decongestants. In: Vassallo J, ed. Immunology and Allergy Clinics of North America. W.B. Saunders Company. 2000;355-68.
19. Gentile DA, Friday GA, **Skoner DP**. Management of allergic rhinitis. Immun and Allergy Clinics of NA 2000; Vol. 20-2.
20. Gentile DA, **Skoner DP**. Limitations of human experimental provocation models for investigating the virus-asthma link. In: **Skoner DP**, ed. Asthma and Respiratory Infections. Marcel-Dekker, Inc. 2001.
21. Gentile DA, **Skoner DP**. Sinusitis and asthma. In: Busse W, Gern J, eds. Asthma, YourDoctor.com. 2001.
22. Gentile DA, **Skoner DP**. Otitis media: clinical evaluation of patients with allergic disease. In: Lockey R, ed. Allergic Diseases, YourDoctor.com . 2001.
23. **Skoner DP**. Issues and challenges in pediatric asthma. Allergy 2001; 56(S66):18-21.
24. **Skoner DP**. Management and treatment of pediatric asthma: Update. Allergy and Asthma Proceedings 2001; Vol.22-2:71-74
25. **Skoner DP**. Why we must do a better job controlling asthma. Contemporary Pediatrics 2001;18-8:49-62.
26. **Skoner DP**. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108(s1):S2-8.
27. Cohen S, Brissette I, **Skoner DP**, Doyle W. Social integration and health: The case of the common cold. 2001; J Social Struc (www.heinz.cmu.edu/project/INSNA/joss/index1.html).
28. **Skoner DP** Challenges in pediatric asthma management: and introduction. Ped Pulmon 2001; 32(S21):49-62.
29. **Skoner DP**. Montelukast in 2- to 5-year-old children with asthma. Ped Pulmon 2001;32;(S21):46-48.
30. **Skoner DP**. Growth effects of asthma and asthma therapy. Cur Opin Pulm Med 2002; 8:45-49.
31. **Skoner DP**. Update of growth effects of inhaled and intranasal corticosteroids. Cur Opin Allergy & Clin Immun 2002;2:7-10.
32. **Skoner DP**. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002; 109(2):381-392.
33. **Skoner DP**. Outcome measures in childhood asthma. Pediatrics 2002; 109(2):393-398.
34. Gentile DA, Michaels M, **Skoner DP**. Allergy and Immunology. In Zitelli BJ, Davis HW, eds. Atlas of Pediatric Physical Diagnosis. Mosby-Wolfe. 2002.
35. Ratner P, Ehrlich P, Fireman S, Meltzer E, **Skoner DP**. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002; 77(4):350-354.
36. **Skoner DP**. Viral Infection and allergy: lower airway. Allergy and Asthma Proc 2002; Vol.23 (4):229-232.
37. Robinson JD, Antelini BL, Krahnke JS, **Skoner DP**. Inhaled steroids and the risk of adrenal suppression in children. Expert Opin 2002; 1(3):1-8.
38. Krahnke J, **Skoner DP**. Benefit and Risk Management for Steroid Treatment in Upper Airway Diseases. Cur

- Allergy and Asthma Report 2002; 2:507-512.
39. Cohen S, Doyle WJ, Turner R, Alper CM, **Skoner DP**. Sociability, social interaction and susceptibility to the common cold. *Psychol Sci* 2003; 14 (5):389-395.
40. Gentile DA, **Skoner DP**. Effect of respiratory syncytial virus infection during early infancy on the ontogeny of cytokine immune response. *Allergy and Asthma Proc*, Nov-Dec 2002.
41. Laughlin GM, **Skoner DP**, Guest Eds. Asthma in children. In: Consensus in Pediatrics. L.G. Feld and J.S. Hyams (eds), Mead Johnson & Co., 2002.
42. Fausnight TB, Gentile DA, **Skoner DP**. Determining the cause of recurrent wheezing in infants. *J Respir Dis Pediatr* 2002;4:126-131.
43. Raff H, Homar P, **Skoner DP**. New enzyme immunoassay for salivary cortisol. *Clin Chem* 2003; 49:203-204.
44. Pawankar R, **Skoner DP**, Eds. Upper airway diseases. *Current Opinion Allergy Clin Immunol* 2003; 3 (1).
45. Casselbrant M, Gentile DA, Mendel E, **Skoner DP**. Otitis media. In: Middleton, et al, eds. *Middleton's Allergy: Principles and Practice*, 6th Edition. Harcourt Health Sciences, 2003.
46. **Skoner DP** (ed). Otitis. *Cur Allergy & Asthma Reports* 2003; 3 (4):314-340.
47. **Skoner DP** (ed). Otitis. Viruses and acute otitis media. *Curr Allergy Asthma Rep* 2004;4(4):293-302.
48. **Skoner DP**. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. *Pediatrics* 2005;115(2):512.
49. **Skoner DP** (ed). Otitis. *Cur Allergy & Asthma Reports* 2005; 5 (4):301-318.
50. **Skoner DP** (ed). Glucocorticosteroids in allergic inflammation. In: *Immunology and Allergy Clinics of North America*. W.B. Saunders Company. 2005; 25 (3):451-620.
51. Doyle WJ, **Skoner DP**, Gentile D. Nasal cytokines as mediators of illness during the common cold. *Cur Allergy and Asthma Reports* 2005;5:173-181.
52. **Skoner DP**. Asthma. In: *Atlas of Allergies and Clinical Immunology*. P. Fireman and R. Slavin (eds), Mosby, Inc. Press, Third Edition, 2006.
53. **Skoner DP**, Pawankar R (eds). Upper airway disease. *Cur Opin Allergy, & Clin Immunol* 2006; 6 (1): 1-11.
54. **Skoner DP**. Treating allergic rhinitis: Current challenges and future approaches. *Clinical Update (CME) Medscape* (www.medscape.com), 2006.
55. **Skoner DP**, Gentile DA. Viral Rhinitis. In: *Current Review of Rhinitis*. MA Kaliner (ed), Current Medicine LLC, 2nd. Edition, 2006.
56. **Skoner DP** (ed). Otitis. *Cur Allergy & Asthma Rep* 2006; 6 (4):315-341.
57. **Skoner DP**. Breast-feeding duration and decreased respiratory tract infections in children. *Cur Allergy & Asthma Rep* 2006; 6(4):315.
58. Lieberman P, Bielory L, Blaiss M, Fineman S, Ledford D, Simmons E, **Skoner D**, Storms W. Concerns about intranasal corticosteroids for over-the-counter use: Position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. *Ann Allergy, Asthma & Immunol* 2006;96:514-525.
59. Doyle WJ, Gentile DA, **Skoner DP**. Viral and bacterial rhinitis. *Clin Allergy Immunol* 2007;19:177-195.
60. **Skoner DP** (ed). Otitis. *Cur Allergy & Asthma Rep* 2007; 7 (6):435-456.
61. Pawankar R, **Skoner DP**, Eds. Upper airway diseases. *Current Opinion Allergy Clin Immunol* 2007; 7 (1):1-42.
62. Pawankar R, **Skoner DP**, Eds. Upper airway diseases. *Current Opinion Allergy Clin Immunol* 2008; 8 (1):1-38.

PUBLISHED ABSTRACTS

1. **Skoner DP**, Fischer T: The usefulness of an index to predict hospitalization of children with acute asthma. *J Allergy Clin Immunol* 73(1) (part 2):121, 1984.
2. Chamovitz A, **Skoner D**, Ackerman M, Green D, Galloway J, Fireman P: Human insulin in management of animal insulin allergy. *J Allergy Clin Immunol* 73(1) (part 2):180, 1984.
3. **Skoner DP**, Doyle WJ, Chamovitz A, Fireman P: Eustachian tube obstruction (ETO) after provocative intranasal challenge with house dust mite. *J Allergy Clin Immunol* 75(1) (part 2):111, 1985.
4. **Skoner DP**, Doyle WJ, Tanner EP, Fireman P: Histamine in middle ear fluids. *Ann Allergy* 54(4):350, 1985.
5. Tanner EP, **Skoner D**, Doyle WJ, Fireman P: Histamine in experimentally-induced middle ear effusions in chinchillas. *Ann Allergy* 55:360, 1985.
6. Fireman P, Stillwagon PK, **Skoner DP**, Bluestone CD, Doyle WJ: Immune basis for eustachian tube (ET) obstruction. *Pediatr Res* 19(4) (part 2):273A, 1985 (published, but not read).

7. Radfar N, Friday GA, Chandra R, **Skoner DP**, Stillwagon PK, Fireman P: IDDM and congenital hypogammaglobulinemia (CHGG). *Pediatr Res* 19(4) (part 2):318A, 1985 (published, but not read).
8. Stillwagon P, **Skoner D**, Doyle W, Fireman P: Effect of natural pollen exposure on eustachian tube function. *J Allergy Clin Immunol* 75(1) (part 2):154, 1985.
9. Fireman P, Chamovitz A, **Skoner D**, Greene D, Fineberg SE, Galloway J: Management of insulin allergy. *J Allergy Clin Immunol* 75(1) (Part 2):107, 1985.
10. **Skoner DP**, Doyle WJ, Fireman P: Eustachian tube obstruction (ETO) after histamine nasal provocation - a double blind dose response study. *J Allergy Clin Immunol* 77:181, 1986.
11. Stillwagon P, Sandson N, **Skoner D**, Doyle W, Fireman P: Neutrophil chemotactic factor activity in middle ear effusions. *J Allergy Clin Immunol* 77:183, 1986.
12. **Skoner DP**, Doyle WJ, Tanner EP, Fireman P: Seasonal fluctuations of middle ear histamine in otitis media with effusion (OME). *Pediatr Res* 20(4) (Part 2):321A, 1986.
13. **Skoner DP**, Doyle WJ, Fireman P: Mucosal hyperresponsiveness: A mechanism for eustachian tube obstruction (ETO) in allergic rhinitis (AR). *Pediatr Res* 20(4) (Part 2):300A, 1986.
14. Stillwagon PK, **Skoner DP**, Fireman P: PNP deficiency with normal natural killer cells. *Pediatr Res* 20(4) (Part 2):300A, 1986 (published, but not read).
15. **Skoner DP**, Caliguiri LA, Davis HW, Fireman P: Plasma elevations of a prostaglandin (PG) metabolite in acute bronchiolitis. *Pediatr Res* 21:505A, 1987.
16. **Skoner DP**, Page R, Asman B, Fireman P: Plasma histamine elevations in acute asthma. *Pediatr Res* 21:505A, 1987.
17. **Skoner DP**, Page R, Asman B, Caliguiri L, Fireman P: Plasma elevations of a prostaglandin (PG) F2alpha metabolite in acute asthma (AA). *J Allergy Clin Immunol* 79:256, 1987.
18. Fireman P, **Skoner D**, Boehm S, Doyle WJ: Late phase responses of the nose, eustachian tube (ET) and lung after nasal allergen challenge. *J Allergy Clin Immunol* 79:258, 1987.
19. Doyle WJ, **Skoner D**, Boehm S, Fireman P: The effect of methacholine challenge on nasal conductance and eustachian tube (ET) function. *J Allergy Clin Immunol* 79:258, 1987.
20. Friday G, Stillwagon P, Page R, Asman B, **Skoner D**, Fireman P: Increased hospitalizations for asthma without increased deaths at Pittsburgh Children's Hospital from 1968-1975. *J Allergy Clin Immunol* 79:182, 1987.
21. Page R, Friday G, Stillwagon P, **Skoner D**, Caliguiri L, Fireman P: Improvement of asthma in IgG subclass deficient asthmatics following IgG replacement therapy. *J Allergy Clin Immunol* 79:188, 1987.
22. **Skoner D**, Page R, Asman B, Fireman P: Increased inflammatory mediators in acute asthma (AA) -sequence of elaboration. *Am Rev Respir Dis* 135:A388, 1987 (published, but not read).
23. **Skoner D**, Caliguiri L, Davis H, Fireman P: Increased inflammatory mediators in acute bronchiolitis: sequence of elaboration. *Am Rev Respir Dis* 135:A466, 1987 (published, but not read).
24. Van Cauwenberg PB, Rihoux JP, Doyle WJ, **Skoner DP**, Tanner E: Effect of cetirizine and cimetidine on the cutaneous reactivity of the rhesus monkey to histamine, 48/80, substance P and VIP. *Clin Exp Dermatol* 12:149, 1987.
25. Asman BJ, **Skoner DP**, Fireman P: Neutrophil chemotactic factor (NCF) in acute bronchiolitis (AB). *Ann Allergy* 58:294, 1987.
26. **Skoner DP**, Caliguiri L, Davis H, Fireman P: Plasma elevations of histamine (HIST) and a prostaglandin (PG) metabolite in acute bronchiolitis (AB). *Pediatr Res* 23(4) (Part 2):568A, 1988.
27. **Skoner DP**, Sweeney WE, Avner ED, Fireman P: Platelet (PLT) transport enzyme abnormalities in asthma and allergic rhinitis (AR). *Pediatr Res* 23(4) (Part 2):568A, 1988 (published, but not read).
28. **Skoner DP**, Boehm S, Doyle WJ, Fireman P: Late phase eustachian tube (ET) and nasal allergic responses associated with inflammatory mediator (IM) elaboration. *J Allergy Clin Immunol* 81:283, 1988.
29. Fireman P, **Skoner DP**, Boehm S, Doyle WJ: Priming of nose and eustachian tube (ET) to intranasal challenge. *J Allergy Clin Immunol* 81:284, 1988.
30. **Skoner D**, Boehm S, Doyle W, Fireman: Nasal and eustachian tube (ET) late allergic responses. *N Eng Regional Allergy Proc* 9(4):300, 1988.
31. **Skoner D** and Gentile D: Inhibition of the sodium-potassium adenosine triphosphatase (Na,K ATPase) pump by plasma of allergic subjects. *J Allergy Clin Immunol* 83(1):311, 1989.
32. Gentile D, **Skoner D**: Defective function of the sodium potassium adenosine triphosphatase (Na,K ATPase) pump in allergy. *J Allergy Clin Immunol* 83(1):311, 1989.
33. Steinberg M, **Skoner D**, Casselbrant M, Gleich G and Fireman P: Eosinophil derived inflammatory mediators (IMs) in children with chronic otitis media with effusion (OME). *J Allergy Clin Immunol* 83(1):207, 1989.
34. Lee L, **Skoner D**, Doyle W and Fireman P: Nasal physiology and inflammatory mediators during natural grass

- exposure. *J Allergy Clin Immunol* 83(1):280, 1989.
35. Fireman P, **Skoner D** and Boehm S: Effect of intranasal beclomethasone dipropionate and cromolyn on allergic rhinitis after antigen provocation. *J Allergy Clin Immunol* 83(1):308, 1989.
 36. Doyle W, **Skoner D**, Tanner and Fireman P: A monkey model of allergic rhinitis. *J Allergy Clin Immunol* 83(1):304, 1989.
 37. **Skoner D**, Gentile D: Defective function of the sodium potassium adenosine triphosphatase (Na,K ATPase) pump in allergy/asthma. *Pediatr Res* 25(4) (Part 2):372A, 1989.
 38. Fireman P, Steinberg M, **Skoner D**, Casselbrant M, Gleich G: Eosinophil derived inflammatory mediators in chronic middle ear effusion (MEF). *Pediatr Res* 25(4):163A, 1989.
 39. Sukanich AC, **Skoner DP**, Doyle WJ, Boehm S, Fireman P: Eustachian tube (ET) function after intranasal histamine in children and adults with allergic rhinitis (AR). *Ann Allergy* 62:247, 1989.
 40. Friday G, Kumer S, **Skoner D**, Fireman P: Asthma and selective IgG subclass deficiency: Further results of intravenous gamma globulin (IVGG) replacement therapy. *J Allergy Clin Immunol* 85(1):234, 1990.
 41. Boehm S, **Skoner D**, Doyle W, Fireman P: Airway physiologic changes after nasal allergen challenge. *J Allergy Clin Immunol* 85(1):289, 1990.
 42. Lin MS, Tanner E, Lynn J, Graham C, **Skoner D**, Fireman P: Prospective studies on systemic reactions (SR) in patients receiving skin testing and immunotherapy (IM). *J Allergy Clin Immunol* 85(1):180, 1990.
 43. Otte R, Casselbrant M, **Skoner D**, Doyle W, Haddad J, Schwartz L, Fireman P: Mast cell-derived inflammatory mediators in children with chronic otitis media with effusion (OME). *J Allergy Clin Immunol* 85(1):223, 1990.
 44. **Skoner D**, Boehm S, Doyle W, Fireman P: Effect of chlorpheniramine (CHL) on airway physiology and symptoms during natural pollen exposure. *J Allergy Clin Immunol* 85(1):158, 1990.
 45. **Skoner D**, Gentile D: Inhibition of the sodium-potassium adenosine triphosphatase (Na, K ATPase) pump in allergy/asthma. *Am Rev Respir Dis* 141(4):A105, 1990.
 46. **Skoner D**, Doyle W, Fireman P: Effect of chlorpheniramine (CHL) on airway physiology and symptoms during natural pollen exposure. Abstracts of 13th Mid-Winter Research Meeting, Association for Research in Otolaryngology, February 1990, St. Petersburg Beach, Florida.
 47. Lower T, Otte R, Casselbrant M, **Skoner D**, Schwartz L, Sigurdardottir S, Fireman P: Inflammatory mediators in children with otitis media with effusion (OME). *J Allergy Clin Immunol* 87(1):220, 1991.
 48. **Skoner D**, Whiteside T, Herberman R, Kiss J, Doyle W, Fireman P: Effect of rhinovirus 39 infection on immune/inflammatory cell functions. *J Allergy Clin Immunol* 87(1):306, 1991.
 49. Doyle W, **Skoner D**, Gwaltney J, Seroky J, Green I, Fireman P: Effect of rhinovirus 39 infection on airway pathophysiology. *J Allergy Clin Immunol* 87(1):246, 1991.
 50. Tanner E, Doyle W, **Skoner D**, Fireman P: Middle ear response to nasal provocation in ascaris sensitized cynomolgus monkeys. *J Allergy Clin Immunol* 87(1):342, 1991.
 51. Gentile D, Braun E, **Skoner D**: Effect of Na⁺, K⁺ ATPase inhibition on leukocyte histamine release (LHR). *J Allergy Clin Immunol* 87(1):158, 1991.
 52. **Skoner D**, Seroky J, Doyle W: Home-based telemetry objectively determines cough characteristics in children with asthma. *Pediatr Res* 29:378A, 1991.
 53. Gentile D, Braun E, **Skoner D**: Leukocyte histamine release (LHR) is enhanced by sodium-potassium adenosine triphosphatase enzyme (Na⁺, K⁺ ATPase) inhibition. *Pediatr Res* 29:156A, 1991.
 54. **Skoner DP**, Gentile DA: Sodium-potassium adenosine triphosphatase enzyme (Na, K ATPase) inhibition enhances airway hyperreactivity (AHR). *Pediatr Res* 29:377A, 1991.
 55. **Skoner DP**, Whiteside T, Herberman R, Kiss JE, Doyle WJ, Fireman P. Rhinovirus 39 (RV) infection alters immune/inflammatory cell functions. *Pediatr Res* 29:163A, 1991.
 56. **Skoner D**, Seroky J, Doyle W: Use of home-based telemetry to objectively determine cough characteristics in children with asthma. *Am Rev Respir Dis* 143(4):A20, 1991.
 57. **Skoner D**, Gentile D: Relationship between airway hyperreactivity (AHR) and sodium-potassium adenosine triphosphatase (Na, K ATPase) pump inhibition. *Am Rev Respir Dis* 143(4):A133, 1991.
 58. Fireman P, **Skoner D**, Doyle W: Effect of rhinovirus (RV) 39 infection on responses of the lower airway and the leukocyte. *Am Rev Respir Dis* 143(4):A420, 1991.
 59. Gentile D, **Skoner D**, Jin R, Karol M: Inhibition of guinea pig platelet sodium-potassium adenosine triphosphatase (Na,K ATPase) activity by allergic human plasma. *Am Rev Respir Dis* 143(4):A241, 1991.
 60. Griffiths-Johnson D, **Skoner D**, Lieb A, Karol M: Parallel induction of airway hyperreactivity (AHR) by ouabain in guinea pigs and humans. *Am Rev Respir Dis* 143(4):A133, 1991.

61. Igarashi Y, **Skoner D**, Fireman P, Doyle W, White M, Kaliner M: Phases of nasal secretions during upper respiratory viral infections. *Am Rev Respir Dis* 143(4):A757, 1991.
62. **Skoner D**, Doyle W, Seroky J, Fireman P: Effect of seasonal ragweed (RW) exposure on the response to nasal ragweed challenge. *J Allergy Clin Immunol* 89:208, 1992.
63. Doyle E, **Skoner D**, Seroky J, Fireman P: Reproducibility of the nasal response to provocative challenge with ragweed (RW) extract. *J Allergy Clin Immunol* 89:208, 1992.
64. Gentile D, **Skoner D**, Brown C: In vitro modulation of Na, K ATPase enzyme activity by anti-allergy drugs. *J Allergy Clin Immunol* 89:237, 1992.
65. Fireman P, **Skoner DP**, Doyle WJ, Hayden F, Buchman CA: Nasal and otologic effects of influenza A virus infection. *J Allergy Clin Immunol* 91(1):191, 1993.
66. Vayonis AG, Doyle WJ, **Skoner DP**, Seroky JT, Fireman P: Intranasal histamine and methacholine in children with and without allergy. *J Allergy Clin Immunol* 91(1):192, 1993.
67. Doyle WJ, **Skoner DP**, Gwaltney JM, Fireman P: Effect of rhinovirus 39 (RV) and influenza virus (IV) infection on lower airway pathophysiology. *J Allergy Clin Immunol* 91(1):351, 1993.
68. **Skoner DP**, Whiteside T, Herberman R, Doyle WJ, Hayden F, Fireman P: Nasal interleukin (IL) levels during experimental influenza virus infection. *J Allergy Clin Immunol* 91(1):191, 1993.
69. Gentile DA, **Skoner DP**: A role for the sodium, potassium adenosine triphosphatase (Na,K ATPase) enzyme in degranulation of rat basophilic leukemia (RBL) cells. *J Allergy Clin Immunol* 91(1):331, 1993.
70. Henry J, Gentile DA, Park A, **Skoner DP**: Inhibition of sodium, potassium adenosine triphosphatase (Na,K ATPase) enzyme activity decreases interleukin-2 (IL-2) release from human lymphocytes. *J Allergy Clin Immunol* 91(1):254, 1993.
71. Gentile DA, **Skoner DP**, Henry J, Park A: Inhibition of sodium, potassium adenosine triphosphatase (Na,K ATPase) modulates inflammatory cell (IC) mediator release. *Pediatr Res* 33(#4, part 2):153A, 1993.
72. **Skoner DP**, Doyle WJ, Hayden F, Buchman CA, Seroky JT, Fireman P: Otitis media (OM) as a manifestation of experimental influenza A virus infection. *Pediatr Res* 33(#4, part 2):183A, 1993.
73. Doyle WJ, Canestrari DA, **Skoner DP**, Seroky J, Miller RD, Riker DK: Temporal patterning of cough in children with acute upper respiratory infections. *Am Rev Respir Dis* 147(4):A134, 1993.
74. Canestrari DA, Doyle WJ, **Skoner DP**, Seroky J, Miller RD, Riker DK: Temporal patterning of cough in adults with acute upper respiratory infections. *Am Rev Respir Dis* 147(4):A135, 1993.
75. **Skoner DP**, Doyle WJ, Hayden F, Buchman CA, Seroky JT, Fireman P: Nasal and otologic effects of influenza A virus infection. Abstracts of 16th Mid-Winter Research Meeting, Association for Research in Otolaryngology, Feb. 1993, St. Petersburg, Florida.
76. Fireman P, **Skoner D**, Tanner E, Doyle W: Effect of influenza A virus (FLU) and rhinovirus 39 (RV-39) infections on leukocyte histamine release (LHR), plasma histamine and total serum immunoglobulin E (IgE) in allergic rhinitis and non-allergic rhinitis subjects. *J Allergy Clin Immunol* 93(1)(part 2):194, 1994.
77. Gentile D, **Skoner D**, Whiteside T, Herberman R, Wilson J, Doyle W, Fireman P: Effect of influenza A virus (FLU) infection on lymphocyte phenotype and function. *J Allergy Clin Immunol* 93(1)(part 2):203, 1994.
78. Katz A, Gentile D, Olinsky S, **Skoner D**: Digoxin inhibits phytohemagglutinin (PHA)-induced proliferation of lymphocytes in allergic rhinitis (AR) and non-AR subjects. *J Allergy Clin Immunol* 93(1)(part 2):204, 1994.
79. Doyle W, **Skoner D**, Tanner E, Fireman P: Lack of nasal priming after experimental ragweed challenge. *J Allergy Clin Immunol* 93(1)(part 2):236, 1994.
80. **Skoner D**, Boltansky H, Kobayashi H, Pearlman D, Shapiro G, Harrison J, Trochelman L: Extended release albuterol sulfate in children with bronchial asthma. *J Allergy Clin Immunol* 93(1)(part 2):249, 1994.
81. **Skoner DP**, Whiteside TL, Wilson JW, Herberman RB, Doyle WJ, Fireman P: Immunosuppression during experimental influenza A virus infection. *Pediatr Res* 35(#4, part 2):16A, 1994.
82. **Skoner DP**, Doyle WJ, Seroky JT, Fireman P, Gwaltney JM: Effect of experimental rhinovirus 39 infection on the nasal response to histamine and cold air challenges in allergic and nonallergic subjects. Abstracts of 17th Mid-Winter Research Meeting, Association for Research in Otolaryngology, Feb. 1994, St. Petersburg, Florida.
83. Whiteside TL, **Skoner DP**, Wilson JW, Doyle WJ, Herberman RB, Fireman P: Differential effects of local infection with influenza A virus and rhinovirus on systemic natural immunity in man. Abstracts of the Second Meeting of The Society of Natural Immunity (Taormina, Italy), 1994.
84. Buchman CA, Doyle WJ, **Skoner DP**, Post JC: Influenza A virus-induced acute otitis media. *Otolaryngol Head Neck Surg* 111(2):125, 1994.
85. Goto MM, Gentile DA, Yellon RF, **Skoner DP**: Inhibition of sodium, potassium adenosine triphosphatase enzyme

- activity by middle ear effusions of children with otitis media. *Otolaryngol Head Neck Surg* 111(2):137, 1994.
86. **Skoner DP**, Angelini BL, Jones A, Seroky J, Doyle WJ, Fireman P: Effect of influenza A virus (FLU) infection on cell-mediated immunity in allergic rhinitis (AR) and non-AR subjects. *J Allergy Clin Immunol* 95(1)(part 2):204, 1995.
87. Wadowsky RM, Mietzner SM, **Skoner DP**, Doyle WJ, Fireman P: Experimental influenza A virus infection alters oropharyngeal bacteria in allergics and non-allergics. *J Allergy Clin Immunol* 95(1)(part 2):204, 1995.
88. Fireman P, **Skoner DP**, Doyle WJ, Seroky J, Hayden F, Gwaltney JM: Effect of rhinovirus 39 (RV) and influenza virus (FLU) infections on the lower airways in allergic rhinitis (AR) and non-AR subjects. *J Allergy Clin Immunol* 95(1)(part 2):389, 1995.
89. Gorby R, Puglielli E, Rau K, Gentile D, **Skoner DP**, Tharp M: Modulation of human mast cell histamine release (HR) by Na⁺,K⁺ adenosine triphosphatase (ATPase) enzyme inhibitors. *J Allergy Clin Immunol* 95(1)(part 2):298, 1995.
90. Gentile DA, **Skoner DP**: Inhibition of the Na⁺,K⁺ adenosine triphosphatase (ATPase) enzyme in peripheral blood mononuclear cells (PBMNC) of allergic rhinitis (AR) subjects. *J Allergy Clin Immunol* 95(1)(part 2):301, 1995.
91. **Skoner DP**, Doyle WJ, Seroky JT, Fireman P: Reproducibility of the effects of intranasal ragweed challenges in allergic subjects. Abstracts of 18th Mid-Winter Research Meeting, Association for Research in Otolaryngology, Feb. 1995, p. 51, St. Petersburg Beach, Florida.
92. Post JC, Aul JJ, White GJ, Wadowsky RD, Doyle WJ, Fireman P, **Skoner DP**, Buchman CA, Ehrlich GD: Differential colonization of the human nasopharynx by *Streptococcus pneumoniae* and *Hemophilus influenzae* following Influenza A virus challenge. Abstracts of 18th Mid-Winter Research Meeting, Association for Research in Otolaryngology, Feb. 1995, p. 51, St. Petersburg Beach, Florida.
93. Alper CM, Doyle WJ, Seroky JT, Buchman CA, **Skoner DP**, Cohen SA: The effect of pre-challenge antibody levels on the response of the nasal airway and middle ear to experimental rhinovirus infection. Abstracts of 18th Mid-Winter Research Meeting, Association for Research in Otolaryngology, Feb. 1995, p. 90, St. Petersburg Beach, Florida.
94. Shibayama Y, Suehiro S, Konishi JE, **Skoner D**, Fireman P, Kaplan AP: Bradykinin generation during viral rhinitis. In Press, 1995.
95. Seiler BA, Angelini BL, Van Deusen M, Cordero KM, Wood L, **Skoner DP**: Effect of oral immunotherapy (O-IT) on short ragweed (SR) pollen allergy. *J Allergy Clin Immunol* 97 (1) (part 3):206, 1996.
96. Patel A, Gentile D, **Skoner DP**: Inhibition of Sodium, Potassium Adenosine Triphosphatase (Na⁺, K⁺, ATPase) Downregulated Proliferation of Peripheral Blood Mononuclear Cells (PBMNC) and Subsets. *J Allergy Clin Immunol* 97 (1) (part 3):418, 1996.
97. Gentile D, Ollila C, Calhoun W, **Skoner DP**: A Sodium, Potassium Adenosine Triphosphatase Inhibitor (Na⁺, K⁺ ATPase INH) in Bronchoalveolar Lavages (BAL) of Asthmatics Following Segmental Allergen Challenge (SAC). *J Allergy Clin Immunol* 97 (1) (part 3):432, 1996.
98. **Skoner DP**, Shibayama Y, Doyle W, Seroky J, Fireman P, Cohen S, Kaplan A: Effect of experimental rhinovirus 39 (RV-39) infection on nasal bradykinin (BK) levels. *J Allergy Clin Immunol* 97 (1) (part 3):495, 1996.
99. Van Deusen M, Angelini BL, Doyle WJ, Seroky J, Cohen S, **Skoner DP**: Effect of Hanks Rhinovirus (RH-V) Infection on the Lower Airways in Allergic (AR) and Non-AR Subjects. *J Allergy Clin Immunol* 97 (1) (part 3):497, 1996.
100. Henry J, Seroky J, Doyle WJ, **Skoner DP**: Cough count (CC) as an objective outcome parameter for controlled clinical trials (CCT) of asthma therapy. *J Allergy Clin Immunol* 97 (1) (part 3):545, 1996.
101. **Skoner DP**, Doyle WJ, Seroky JT, Cohen S: Comparison of the middle ear response to experimental infection with rhinovirus (RV)-39 and RV-Hanks. Abstracts of 19th Mid-Winter Research Meeting, Association for Research in Otolaryngology, p. 147, St. Petersburg Beach, Florida, Feb. 1996.
102. Yuta A, Van Deusen M, Gaumond E, Ali JN, Baraniuk JN, Doyle WJ, Cohen S, **Skoner DP**: Vascular Permeability and Mucous Hypersecretion After Rhinovirus Infection. *Amer J Resp Crit Care Med* 153:A865, 1996.
103. Gentile D, Ollila C, Calhoun W, **Skoner DP**: Segmental Allergen Challenge (SAC) of Allergic Subjects Induces the Elaboration of a Sodium, Potassium Adenosine Triphosphatase Enzyme Inhibitor (Na⁺, K⁺ ATPase INH) in Bronchoalveolar Lavage (BAL) Fluid. *Amer J Resp Crit Care Med* 153:A877, 1996.
104. Cordero KM, Angelini BL, Cohen S, Doyle WJ, **Skoner DP**: Comparison of Subject-Reported Allergy Versus Skin Test Results in a Common Cold Trial. *J Allergy Clin Immunology* 99:S60, 1997.
105. Angelini BL, Van Deusen MA, Gentile DA, **Skoner DP**: Effect of Blinding on Reproducibility of Knemometry When Used to Measure Short Term Growth. *J Allergy Clin Immunology* 99:S59, 1997.

106. Sidhu RK, Angelini BL, Van Deusen MA, Cordoro K, Wood L, **Skoner DP**. Long-Term Serological Effects of Oral Immunotherapy (O-IT) in Patients with Short Ragweed (SR) Allergy. *J Allergy Clin Immunology* 99:S63, 1997.
107. Gentile DA, Patel A, Ollila C, Fireman PF, Doyle WJ, **Skoner DP**. Diminished IL-10 Production in Allergic Rhinitis (AR) Subjects During Influenza A Virus (FLU) Infection. *J Allergy Clin Immunology* 99:S169, 1997.
108. **Skoner DP**, Fireman PF, Doyle WJ. Urine Histamine Metabolite Elevations During Experimental Colds. *J Allergy Clin Immunology* 99:S419, 1997.
109. **Skoner DP**, Gentile D, Patel A, Doyle W. Evidence for cytokine mediation of symptoms in adults experimentally infected with influenza A (FLU) virus. *J Allergy Clin Immunol* 101(1)(part2):S109, 1998.
110. Gentile D, Allen G, Patel A, Doyle W, Zeevi A, **Skoner DP**. Elevations of local cytokine protein and mRNA levels in adults experimentally infected with influenza A (FLU) virus. *J Allergy Clin Immunol* 101(1)(part2):S150, 1998.
111. Belenky S, Gentile D, Doyle W, Patel A, Hayden F, **Skoner DP**. Effect of rimantadine ((RIM) on specific serum hemagglutination-inhibition (S-HI and nasal IgA (N-IgA)) antibodies induced by experimental exposure of adults to influenza A (FLU) virus. *J Allergy Clin Immunol* 101(1)(part2):S151, 1998.
112. Fireman P, **Skoner DP**, Angelini B, Seroky J, Doyle W. Pre-existing eustachian tube dysfunction (ETD) promotes otologic complications after experimental viral infection. *J Allergy Clin Immunol* 101(1)(part2):S225, 1998.
113. Paulukonis EA, Angelini BL, Seroky J, Doyle WJ, **Skoner DP**, Fireman P. Effect of cloistering on the response to experimental influenza challenge. *J Allergy Clin Immunol* 101(1)(part2):S2, 1998.
114. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris RM, Seltzer JM, **Skoner DP**, Storms WW, Wood RA. An evaluation of the effects of beclomethasone Dipropionate aqueous nasal spray {Vancenase AQ (VNS)} on long-term growth in children. *J Allergy Clin Immunol* 101(1)(part2):S236, 1998.
115. **Skoner DP**, Gentile DA, Patel A. Evidence for cytokine mediation of symptoms in adults experimentally infected with influenza A (FLU) virus. Assoc for Research in Otolaryngology, Tradewinds Hotel 2/15-19, 1998, St. Petersburg Beach FL, page 108.
116. Ranck HM, Cordoro KM, Paulukonis EA, Angelini BA, Gentile DA, Cohen S, **Skoner DP**. Effect of stress on the response to bronchial methacholine challenge in asthma. *J Allergy Clin Immunol* 1998;101:S112.
117. Gentile D, Patel A, Doyle W, Allen G, Zeevi A, **Skoner D**. Elevated interleukin-6 (IL-6) production following experimental infection with influenza A (FLU) virus. *Am J Resp Crit Care Med* 1998;157:A616.
118. Belenky S, Gentile D, Doyle W, Patel A, Hayden F, **Skoner D**. Rimantadine effect on specific serum hemagglutination inhibition and nasal IgA antibodies in experimental influenza A (FLU) virus exposure of adults. *Am J Resp Crit Care Med* 1998;157:A173.
119. Gentile DA, **Skoner DP**, Walton-Bowen KL, Cruz-Rivera M. The efficacy & safety of once daily Pulmicort RespulesTM (budesonide nebulizing suspension) and placebo in infants and young children with persistent asthma. *Pediatr Res* 1998;43(4):A332.
120. Gentile DA, Allen G, Patel A, Zeevi A, Doyle W, **Skoner DP**. Elevations of local leukotriene C4 and pro-inflammatory cytokines in adults experimentally infected with influenza A virus. *Ann Allergy Asthma Immunol* 1999; In Press.
121. Gentile DA, **Skoner DP**, Angelini BL, Patel A, Doyle WJ, Fireman P. Diminished immune responses in adults experimentally infected with RSV. *J Allergy Clin Immunol* 1999;103:S116.
122. Belenky S, **Skoner DP**, Gentile DA, Angelini BL, Doyle WJ, Fireman P. Lower Airway Responses to Respiratory Syncytial Virus (RSV). *J Allergy Clin Immunol* 1999;103:S116.
123. Angelini BL, Gentile DA, Doyle WJ, **Skoner DP**, Fireman P. Upper Airway Responses to Respiratory Syncytial Virus (RSV). *J Allergy Clin Immunol* 1999;103:S173.
124. Ranck HM, Angelini BL, Paulukonis EA, Gentile DA, Lorber R, **Skoner DP**. Cough patterns in seasonal allergic rhinitis patients assessed by home-based telemetry. *J Allergy Clin Immunol* 1999;103:S4.
125. Paulukonis EA, Angelini BL, Ranck HM, Gentile DA, Lorber R, **Skoner DP**. Subjective and objective methods of determining cough frequency in patients with seasonal allergic rhinitis. *J Allergy Clin Immunol* 1999;103:S4.
126. Yokitis JW, Paulukonis EA, Angelini BL, Gentile DA, **Skoner DP**. Temporal mapping of the nasal secretion response to intranasal inoculation with rhinovirus 39. *J Allergy Clin Immunol* 1999;103:S15.
127. Gentile D, Angelini B, Paulukonis B, Ranck H, Georges G, Lim J, **Skoner D**. Feasibility of a 10 month knemometry study to assess the effect of inhaled corticosteroids on lower leg growth in children with asthma. *AJRCCM* 1999;159:A138.
128. Gentile DA, Fireman P, Patel A, Angelini B, Doyle WJ, Buchman C, **Skoner DP**. Temporal relationship between local elevations of pro-inflammatory cytokines and the development of nasal/otologic pathophysiology during experimental infection with respiratory syncytial virus. *Pediatr Res* 1999;45:10A.

129. Lorber R, **Skoner D**, Berger W, Harris AG, Danzig M. Effect of Loratadine + Pseudoephedrine (LP) with and without Guaifenesin (G) in seasonal allergic rhinitis (SAR) patients with cough. *J Allergy Clin Immunology* 1999;103S:114.
130. **Skoner DP**, Welch m, Tinkelman D, Bagchi P, Raudenbush MA, Banerji D. Inhaled corticosteroid-induced growth retardation in asthmatic children in a "real world" setting. *J Allergy Clin Immunology* 1999;103:S61.
131. Gentile DA, Yokitis J, Angelini BL, Doyle WJ, **Skoner DP**. Effect of intranasal challenge with IL-6 on airway symptomatology and physiology in allergic and non-allergic subjects. *Ann Allergy Asthma Immunol* 2000;84:130.
132. Ranck HM, Gentile DA, Patel A, Angelini BL, **Skoner DP**. Elevations of local pro-inflammatory cytokine levels in adults experimentally infected with rhinovirus-39. *J Allergy Clin Immunol* 2000;105:S4.
133. Gentile DA, Doyle WJ, Seroky J, Angelini BL, **Skoner DP**. Elevations of local leukotriene C₄ levels in adults experimentally infected with influenza A virus. *J Allergy Clin Immunol* 2000;105:S199.
134. Villalobos EM, Belenky S, Gentile DA, Piltcher O, Doyle WJ, Ranck HM, **Skoner DP**, Fireman P. Local nitric oxide levels during experimental intranasal challenge with respiratory syncytial virus in adult subjects. *J Allergy Clin Immunol* 2000;105:S199.
135. Kelly TC, Gentile DA, Angelini BL, Seroky JT, Doyle WJ, **Skoner DP**, Fireman P. Effect of experimental respiratory syncytial virus inoculation on the nasal response to histamine challenge in adult subjects. *J Allergy Clin Immunol* 2000;105:S199.
136. Lesniak B, Gentile DA, Zeevi A, Fireman P, Seroky J, Doyle WJ, **Skoner DP**. TNF- α polymorphisms and susceptibility to illness in adults experimentally infected with influenza A virus. *J Allergy Clin Immunol* 2000;105:S200.
137. **Skoner DP**, Gentile DA, Doyle WJ, Ranck HM, Frieko L, Piltcher O, Angelini BL, Fireman P. Enhanced immediate hypersensitivity skin responses during experimental challenge with respiratory syncytial virus in adult subjects. *J Allergy Clin Immunol* 2000;105:S356.
138. Exelbert RL, **Skoner DP**, Gentile DA, Doyle WJ, Seroky J, Angelini BL, Fireman P. Upper airway responses in ragweed-primed and unprimed adult subjects during experimental infection with influenza A virus. *J Allergy Clin Immunol* 2000;105:S198.
139. **Skoner D**, Angelini B, Gentile D, Kenyon D. Pediatric airflow profiles with the new mometasone furoate dry powder inhaler. *J Allergy Clin Immunol* 2000;105:S16.
140. Sgritto J, Kelly K, Shira J, **Skoner D**, Kaye R. The Eagle's Circle, a wellness program for children with asthma and/or obesity. *J Allergy Clin Immunol* 2000;105:S6.
141. Gentile DA, Patel A, Doyle WJ, Fireman P, Angelini B, **Skoner DP**. Elevations of local leukotriene C₄ levels during experimental viral upper respiratory infections. *Am J Respir Crit Care Med* 2000;161:A179.
142. Belenky S, Gentile D, Doyle W, Ranck H, Angelini B, Fireman P, **Skoner D**. Altered immediate and delayed hypersensitivity skin responses during experimental challenge with respiratory syncytial virus in adult subjects. *Am J Respir Crit Care Med* 2000;161:A932.
143. Gentile DA, Patel A, Doyle WJ, Fireman P, Angelini B, **Skoner DP**. Elevations of local leukotriene C₄ levels during experimental viral upper respiratory infections. *Pediatr Research* 2000.
144. Belenky S, Gentile D, Doyle W, Ranck H, Angelini B, Fireman P, **Skoner D**. Altered immediate and delayed hypersensitivity skin responses during experimental challenge with respiratory syncytial virus in adult subjects. *Pediatr Reseach* 2000.
145. Schenkel E, Miller D, Angelini B, **Skoner D**, Kenyon D. Assessment of inspiratory flow rates and rise time data in patients with asthma. *Ann Allergy Immuno* Jan 2000.
146. **Skoner D**, Kane R, Stamatiades D, Gentile D, Angelini B, Dvorchik I, Reis E, Banerji D. Intranasal fluticasone propionate 200 mcg/day significantly suppresses HPA axis compared to intranasal triamcinolone acetonide at either 110 or 220 mcg/day. *Euro J Allergy Clin Immuno*. 2000;Suppl 6; Vol 55, page 42.
147. **Skoner D**, Kane R, Stamatiades D, Gentile D, Angelini B, Dvorchik I, Reis E, Banerji D. Triamcinolone acetonide aqueous nasal inhaler and fluticasone propionate have no effect on short-term growth in children with allergic rhinitis. *Euro J Allergy Clin Immuno*. 2000;Suppl 6; Vol 55, page 184.
148. **Skoner D**. Long-Term Treatment With Mometasone Furoate Nasal Spray Does Not Suppress Growth of Pediatric Patients. 2000; Poster Presentation: The Nose 2000. . .And Beyond Congress.
149. **Skoner DP**, Angelini BL, Gentile DA, Ranck HL, Kelly TC, Datta K, Banerji D. Comparison of the effects of intra nasal triamcinolone acetonide (TAA) and fluticasone propionate (FP) on HPA axis and short-term growth in children with allergic rhinitis. *J Clin Allergy Clin Immunol* 2001: S154.
150. Villalobos EM, Gentile DA, Patel A, Angelini BL, Doyle W, **Skoner DP**. Pro-inflammatory cytokine levels in

- asymptomatic and symptomatic adults experimentally infected with Rhinovirus-39. *J Clin Allergy Clin Immunol* 2001; S154.
151. Gentile DA, Patel A, Angelini BL, Doyle W, Fireman P, **Skoner DP**. Upper airway effects of experimental infection with respiratory syncytial virus (RSV) in adult subjects. *J Clin Allergy Clin Immunol* 2001; S154.
 152. **Skoner DP**, Management and treatment of pediatric asthma: update. *Allergy & Asthma Proc* 2001;Vol 22-2, page 71-74
 153. Gentile DA, **Skoner DP**, Viral rhinitis. *Current Allergy & Asthma Reports* 2001;1:227-234
 154. Gentile DA, Patel A, Doyle WJ, Cohen S, **Skoner DP**. Local pro-inflammatory cytokine levels in uninfected, asymptomatic infected and symptomatic infected adults experimentally inoculated with rhinovirus 39. *J Allergy Clin Immunol* 2002;109:S99.
 155. Fausnight T, Gentile D, Sukaly S, Doyle W, **Skoner DP**. Effect of intranasal challenge with interleukin-1B on upper airway symptoms and physiology in allergic and non-allergic subjects. *J Allergy Clin Immunol* 2002; 109:S262-3.
 156. Kapadia SB, Gentile DA, Howe-Adams J, Trecki J, **Skoner DP**. Relationship between local TNF protein levels and severity of illness during respiratory syncytial virus infection in hospitalized infants. *J Allergy Clin Immunol* 2002; 109:S341.
 157. **Skoner DP**, Gentile DA, Gungor A, Belenky SN, Angelini BL, Richards HM, Hart S, Doyle WJ. The effects of desloratadine (DL) on the allergic inflammatory response of the nasal mucosa associated with seasonal allergic rhinitis (SAR): A nasal mucosal biopsy study (NMBX). *J Allergy Clin Immunol* 2003; 111(2):S83.
 158. Schreiber RL, Gentile DA, Howe-Adams J, Trecki J, Patel A, Fireman P, **Skoner DP**. Diminished dendritic cell (DC) IL-10 production in children with allergic rhinitis (AR) and/or asthma. *J Allergy Clin Immunol* 2003; 111(2):S188.
 159. Howe-Adams J, Gentile DA, Zeevi A, Trecki J, Angelini BL, **Skoner DP**. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus (RSV) infection. *J Allergy Clin Immunol* 2003; 111(2):S270.
 160. Gentile DA, Howe-Adams J, Trecki J, Patel A, Fireman P, **Skoner DP**. Diminished dendritic cell (DC) IL-10 production and enhanced T helper lymphocyte type 2 (Th2) cytokine responses during infancy. *J Allergy Clin Immunol* 2003; 111(2):S280.
 161. **Skoner DP**, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and HPA axis function in children with asthma. *Am J Respir Crit Care Med* 2003; 167 (7): A272.
 162. **Skoner D**, Gentile D, Angelini B, Patel A, Richards H, Mizoguchi H, Doyle W. Association between cytokine responses and frequency of common cold episodes. *J Allergy Clin Immunol* 2004; 113(2):S30.
 163. Otte R, Gentile D, Angelini B, Krahne J, Richards H, Trecki J, Doyle W, **Skoner D**. Effect of levalbuterol on exhaled nitric oxide (NO) levels in asthmatic subjects. *J Allergy Clin Immunol* 2004; 113(2):S32.
 164. Trecki J, Gentile D, Fausnight T, Patel A, Angelini B, **Skoner D**. Effect of tetanus immunization on T helper (Th) cytokine production in adults with and without allergic rhinitis. *J Allergy Clin Immunol* 2004; 113(2):S245.
 165. **Skoner D**, Gentile D, Angelini B, Patel A, Richards H, Mizoguchi H, Doyle W. Association between cytokine responses and frequency of common cold episodes. *J Allergy Clin Immunol* 2004; 113(2):S30.
 166. Otte R, Gentile D, Angelini B, Krahne J, Richards H, Trecki J, Doyle W, **Skoner D**. Effect of levalbuterol on exhaled nitric oxide (NO) levels in asthmatic subjects. *J Allergy Clin Immunol* 2004; 113(2):S32.
 167. Gentile D, Howe-Adams J, Trecki J, Patel A, Angelini B, **Skoner D**. Association between environmental tobacco smoke (ETS) and diminished dendritic cell (DC) IL-10 production during infancy. *J Allergy Clin Immunol* 2004; 113(2):S194.
 168. Trecki J, Gentile D, Fausnight T, Patel A, Angelini B, **Skoner D**. Effect of tetanus immunization on T helper (Th) cytokine production in adults with and without allergic rhinitis. *J Allergy Clin Immunol* 2004; 113(2):S245.
 169. Gentile D, Patel A, **Skoner D**. Association between second-hand smoke exposure and enhanced peripheral blood mononuclear cell IL-13 production during infancy. *J Allergy Clin Immunol* 2005;115(2):S116.
 170. Speer E, Gentile D, Patel A, **Skoner D**. Decreased IL-10 production in cord blood mononuclear cells in preterm infants. *J Allergy Clin Immunol* 2005;115(2):S254.
 171. Ober S, Gentile D, Kairis E, Barnoski K, Doyle W, **Skoner D**. Growth velocity and HPA axis function during 1-year treatment with triamcinolone acetonide aqueous nasal spray in children with allergic rhinitis. *J Allergy Clin Immunol* 2005;115(2):S328.
 172. **Skoner D**, Gentile D, Kairis E, Barnoski K, Buzzard C, Patel A, Doyle W. Association between cytokine gene polymorphisms and otitis media in children with acute respiratory syncytial virus infection. *J Allergy Clin*

- Immunol 2005;115(2):S255.
173. **Skoner DP**, Gentile DA, Doyle WJ, Ober SJ, Buzzard CA, Patel AV, Angelini BA. Effect of 1-year treatment with triamcinolone acetonide aqueous (TAA) nasal spray on growth velocity and HPA function in children with allergic rhinitis (AR). *Annals of Allergy, Asthma & Immunol* 2005;94(1):109.
 174. **Skoner D**, Maspero J, Kundu S, Lloyd M, Banerji D. Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma. *J Allergy Clin Immunol* 2006;117(2):S11.
 175. Koehrsen J, Gentile DA, **Skoner DP**. Effect of levalbuterol on nasal mucociliary transport (MCT) in healthy adult subjects. *J Allergy Clin Immunol* 2006;117(2):S260.
 176. Patel A, Gentile DA, Koehrsen J, **Skoner DP**. Association between TGF-B1 genotype and the development of otitis media (OM) in young children during respiratory virus season. *J Allergy Clin Immunol* 2006;117(2):S318.
 177. Gentile DA, Koehrsen J, Patel A, **Skoner DP**. Association between secondhand smoke exposure (SSE) and increased IL-13 production from CD4+ cells during early childhood. *J Allergy Clin Immunol* 2006;117(2):S257.
 178. **Skoner D**, Baena-Cagnani E, Maspero J. Long-term treatment with ciclesonide once daily has no effect on growth velocity, skeletal maturity and HPA-axis function in children with mild persistent asthma. *Eur Respir J* 2006; 28 (suppl 50): p 711S.
 179. **Skoner D**, Gentile DA, Patel A, Varga MA, Doyle WJ. 3-Year treatment of children with triamcinolone acetonide aqueous for allergic rhinitis does not affect statural growth. *Annals of Allergy Asthma & Immunol* 2007; 98 (1) Suppl 1: A91.
 180. Blaiss M, **Skoner D**, Iezzoni D, Shedden A. Palatability of desloratadine 2.5 mg reditabs vs cetirizine 5 mg chewable tablets in children 6 to 11 years of age. *Annals of Allergy Asthma & Immunol* 2007; 98 (1) Suppl 1: A96.
 181. **Skoner DP**, Gentile DA, Koehrsen JM, Patel A, Varga M, Schad CA, Schaffner TJ. Effect of montelukast on nasal secretion weights during naturally acquired vURIs in adults. *J Allergy Clin Immunol* 2007; 119 (1) Suppl: S315.
 182. Gentile DA, Koehrsen JM, **Skoner DP**, Patel A, Varga M, Schad CA, Schaffner TJ. Effect of treatment with montelukast on otitis media (OM) in children. *J Allergy Clin Immunol* 2007; 119 (1) Suppl: S303.
 183. Koehrsen JM, **Skoner DP**, Gentile DA, Patel A, Varga M, Schad CA, Schaffner TJ. Relationship between IFN- γ genotypes and the development of otitis media (OM) during respiratory syncytial virus (RSV) infection in young children. *J Allergy Clin Immunol* 2007; 119 (1) Suppl: S303.
 184. Patel A, Gentile DA, Koehrsen JM, **Skoner DP**, Varga M, Schad CA, Schaffner TJ. Association between second hand smoke exposure (SSE) and T-helper type 2 (TH2) cytokine production during early childhood. *J Allergy Clin Immunol* 2007; 119 (1) Suppl:S45.
 185. **Skoner DP**, Gentile DA, Angelini B. Twice-daily treatment with mometasone furoate dry-powder inhaler 100 micrograms did not exert a systemic effect as measured by plasma cortisol levels: Findings from a pediatric asthma placebo-controlled clinical trial. *Chest* 2007; 132 Oct (4):602S.
 186. **Skoner D**, Gentile D. Children with mild asthma achieve peak inspiratory flow rates that allow adequate delivery of mometasone furoate from the twisthaler® dry powder inhaler. *Annals of Allergy, Asthma & Immunol* 2008;100(Jan) :A28.
 187. LaForce C, **Skoner D**. Resolution of symptoms in patients with acute respiratory infections receiving antibiotic therapy and Mucinex® D. *Annals of Allergy, Asthma & Immunol* 2008;100(Jan) :A83.
-

EDUCATIONAL ACTIVITIES

TEACHING:

Lecture to pediatric housestaff medical students, nurse practitioner students and physician groups.

Supervision of Allergy/Immunology Fellows-In-Training.

Pediatric Ward attending.

Supervision of Medical Student Summer Research Projects - 1986-1994.

Preceptor - Summer Premedical Academic Enrichment Program-1990

Allergy/Immunology Fellow Research Projects

Allergy/Asthma Grand Rounds, Developed, lecture to housestaff, medical students, nurse practitioner and physician groups, 2003 to present

SUPPORT/RESEARCH

FUNDED GRANTS

United Way	Inflammatory Mediators in Acute Asthma and Broncholitis in Children	P.I., 10%	1985-1987
American Lung Association of PA.	Inflammatory Mediators in Acute Bronchiolitis in Children	P.I., 5%	1985-1986
3MOIRR084 NIH	Inflammatory Mediators in Clinical Acute Bronchitis and Asthma in Children (GCRC)	P.I., 80%	1985-1987
American Lung Association of PA	Inflammatory Mediators in Diseases Associated with Airway Hyperreactivity	P.I., 5%	1987-1989
American Lung Association of PA	Biochemical Mechanisms of Airway Hyperreactivity	P.I., 50%	1989-1991
Richardson-Vicks, USA	An Evaluation of the Comparative Efficacy of Dextromethorphan Hbr and an Aqueous Placebo Control in Children with Acute Coughs due to Colds	P.I., 2%	1990-1991
Schering-Plough Research Institute	Asthma Cough Study-Model Development	P.I., 4%	1990-1991
AI-19262 NIH	Immune Mechanisms of Middle Ear Disease	Co-P.I., 15%	1990-1999
Richardson-Vicks, USA	Temporal Pattern of Coughing in Adults with Upper Respiratory Tract Infections	Co-P.I., 2%	1991-1992
Howard Hughes Medical Institute	Research Training Fellowship for Medical Students: Na,K ATPase in Signal Transduction of Inflammatory Cells	Co-P.I., 2%	1991-1992
Schering-Plough Research Institute	A Study Comparing the Efficacy and Tolerability of Proventil Repetabs Tablets with Placebo in Children with Bronchial Asthma	P.I., 2%	1992-1993
Richardson-Vicks, USA	An Evaluation of the Comparative Efficacy of Dextromethorphan Hbr and an Aqueous Placebo Control Using Telemetry-Based Cough Recording in Adults with Acute Cough Due to Colds	Co-P.I., 2%	1992-1993
Boehringer Ingelheim	A Double-Blind, Vehicle-Controlled Pharmacokinetic Study to Determine the absorption Absorption Characteristics of Ipratropium (Atrovent) Nasal Spray 0.06% Vs Vehicle Administered in Volunteers Infected With Rhinovirus 39	Co-P.I., 2%	1992-1993
UCB Pharma	Effect of Topical UCB 28754 on Rhinitis	Co-P.I., 2%	1992-1993

Provoked by Intranasal Histamine in the Monkey

IRO1 MH50429-01	Stress and Susceptibility to Infectious Disease	Co-P.I., 10%	1993-1996
Immuno Research	Clinical C1-Inhibitor Prophylaxis in Hereditary Angioedema	Co-P.I., 2%	1993-1994
TAP Pharm	Safety and Efficacy of Abbott 73001 in Patients with Moderate Asthma	P.I., 2%	1993-1994
Schering-Plough Research Institute	A Study of the Effects of Intranasal Steroids(Beclomethasone Dipropionate) on the Growth and HPA Axis Function of Children	P.I., 2%	1993-1995
Glaxo- Wellcome, Inc.	A randomized, double-blind, double-dummy comparative clinical trial of 12 week courses of salmeterol xinafoate versus extended-release theophylline versus placebo in adolescent and adult patients with chronic reversible obstructive airways disease	Co-P.I., 2%	1993-1994
Zeneca Pharm	A multicenter, randomized, double-blind study to compare the effect of oral doses of ZD2138 with placebo over 4 weeks in patients with bronchial asthma	P.I., 2%	1993-1994
TAP Pharm	Dose-ranging effect of Abbott 73001 on bronchial hyperresponsiveness to metha-choline choline in patients with moderate asthma	P.I., 2%	1994-1995
Astra	A study of three dose levels of budesonide nebulizing suspension and placebo in asthmatic children aged 8 years and younger	P.I., 2%	1994-1996
Fisons	Effect of Tilade on objectively measured nocturnal coughing and wheezing in asthma	P.I., 5%	1994-1996
Glaxo- Wellcome, Inc.	A Double-Blind, Parallel Group Evaluation Salmeterol Versus Placebo in the Treatment of Nocturnal Asthma	Co-P.I., 1%	1994-1995
Fisons	A multi-center, randomized, double-blind, placebo-controlled, parallel group comparative study of the efficacy and safety of chlorofluorocarbon (CFC) and non-CFC formulations of Intal metered dose inhaler 2 mg q.i.d. in the treatment of moderate asthmatic patients 12 years and older, withdrawn from Intal maintenance therapy	P.I., 2%	1995-1996
Immune-Tech	A study to investigate the efficacy and safety of C1-inhibitor (human) vapor-heated, Immuno as a therapeutic agent in	P.I., 2%	1995-1996

	patients with hereditary angioedema		
Glaxo-Wellcome, Inc.	A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Six Month Clinical Trial to Examine the Efficacy and Safety of Salmeterol Xinafoate 42 mcg bid, Beclomethasone Dipropionate 84 mcg QID, and Placebo in Adolescent and Adult Subjects with Mild to Moderate Asthma	Co-P.I., 1%	1995-1996
TAP Pharm	Dose Ranging Effect of Abbott 73001 on Bronchial Hyperresponsiveness to Methacholine in Patients with Moderate Asthma	P.I., 2%	1995-1996
Allerganics	Oral Immunotherapy with Short Ragweed Pollen Extract Compared with Placebo in Intranasal Ragweed Challenge	P.I., 5%	1995-1996
Fetzer Institute	Stress and Susceptibility to Asthma	Co-P.I., 1%	1995-1996
3M Pharm.	12-Month, Open-Label, Safety and Efficacy of HFA-134a Beclomethasone Dipropionate in Subjects with Asthma	Co-P.I., 1%	1995-1996
Glaxo-Wellcome, Inc.	A Comparison of Adding Serevent Versus Doubling the Dose of Beclovent in Asthmatic Subjects Symptomatic on Their Existing Inhaled Corticosteroids	P.I., 1%	1995-1996
Glaxo-Wellcome, Inc.	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections	P.I., 1%	1995-1996
Glaxo-Wellcome, Inc.	A Randomized, Double-Blind, Parallel-Group, Comparative Trial of Inhaled Fluticasone Propionate and Beclomethasone Dipropionate Via the Metered-Dose Inhaler in Asthmatic Subjects Currently	Co-P.I., 1%	1995-1996
Schering-Plough Research Institute	Dose Ranging Study of Mometasone Furoate Nasal Spray in the Treatment of Children (ages 6-11) with Seasonal Allergic Rhinitis	P.I., 1%	1996-1997
Rhone-Poulenc-Rorer	Assessment of Short-Term Growth in Dose-Ranging, Placebo Controlled, Crossover Study of Triamcinolone Acetonide in Children 6 to 9.5 Years Old with Mild Asthma	P.I., 1%	1996-1998
Schering-Plough Research Institute	Efficacy of Loratadine Syrup in Children (ages 6-12 years) with Seasonal Allergic Rhinitis	P.I., 1%	1996-1997

Schering-Plough Research Institute	One-Year, Evaluation Blind Study of Mometasone Furoate Nasal Spray Versus Beclomethasone Dipropionate in Children (ages 6-11) with Perennial Rhinitis	P.I., 1%	1996-1998
1 RO1 DC NIH 02833-01 NIH/NIDCD	Prevention of Otologic Complications of Influenza A	Co-P.I., 10%	12/96-11/98
Smith Kline Beecham	A double-blind, placebo controlled trial Comparing Contac and Sudafed in adults with viral induced colds.	P.I., 2%	1996-1997
Schering-Plough Research Institute	Claritin-D 12 hour and guaifenesin (600mg BID) alone and in combination versus placebo in patients with seasonal allergic rhinitis and cough.	P.I., 2%	1997-1998
Astra	A safety study of Pulmicort nebulizing suspension in severe, oral steroid-dependent asthmatic patients aged 6 months to 8 years.	P.I., 2%	1997-2000
Astra	A 3 year, open-label safety study of budesonide nebulizing suspension in asthmatic children.	P.I., 2%	1997-2000
Astra	An evaluation of Pulmicort Respules versus Intal in asthma-related outcomes in children 2 to 6 years old.	P.I., 2%	1997-1999
Astra	START - Inhaled steroid treatment as regular therapy in early asthma	P.I., 2%	1997-2002
Section of Allergy/Immunology; Children's Hospital of Pittsburgh	Comparison of short-term growth velocity in mild asthmatic children versus non- asthmatic children aged 6 to 11 years old as measured by knemometry.	P.I.	1997-1999
Schering-Plough	Claritin-D 12-hour and guaifenesin (600 mg BID) alone and in combination versus placebo in patients with seasonal allergic rhinitis and cough.	P.I., 2%	1997-1998
Glaxo-Wellcome	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir in the treatment of influenza A and B viral infections in adolescents and adults.	P.I., 2%	1997-2000
Schering-Plough	Multiple dose safety study of mometasone furoate dry powder (MF-DPI) in asthmatic children.	P.I., 20%	1997

Glaxo-Wellcome	Assessment of short-term growth in a cross-over study of intranasal fluticasone propionate, BDP and placebo in children 6 to 10/10.5 years old with perennial allergic rhinitis.	P.I., 2%	1998-1999
Schering-Plough	One-year, double-blind study of the effects of mometasone furoate dry powder inhaler versus placebo on the growth of children with mild asthma.	P.I., 2%	1998-2000
Zeneca	A multi-center double-blind comparison of zafirlukast with placebo in pediatric subjects with mild to moderate asthma.	P.I., 2%	1998-1999
Merck	A multi-center, double-blind, randomized parallel-group chronic asthma study comparing montelukast with placebo in 2-5 year old patients.	P.I., 2%	1998-2000
NIH/NIMH RO1MH50429-06	"Social Support, Stress and Susceptibility to Infection" The major goal of this study is to evaluate the roles of Social networks, interactions, and interpersonal conflicts and strains in susceptibility to upper respiratory infections	Sub-Invest, 5%	1996-2001
NIH 1P50HL65111	"Psychobiological Pathways: Risks for Respiratory Illness"	Sub-Invest, 15%	1999-2004
Forest Laboratories	"A Placebo Controlled, Single-Blind, Cross-Over Study to Evaluate the Short-Term Growth Effects of Flunisolide and Fluticasone in Pediatric Patients with Mild Asthma"	P.I., 16.8%	1999-2001
Merck	A multicenter, double-blind, randomized, parallel group study comparing the effect on linear growth of montelukast with placebo and inhaled beclomethasone in pediatric patients (Pre-Pubertal, Tanner Stage I) with mild asthma.	P.I., 11.2%	1999-2001
Glaxo Wellcome	A multicenter, randomized, double-blind, parallel-group Study to assess the potential growth effects of a 1 year Course of fluticasone propionate aqueous nasal spray vs. placebo in pediatric patients with PAR	P.I., 11.2%	1999-2001
Glaxo Wellcome	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Study of Fluticasone Propionate 44mcg and 88mcg BID Delivered via MDI and a Valved Holding Chamber in Subjects with Asthma 24 months-47 months.	P.I., 5.6%	1999-2000
TAP	A Study to Compare the Safety and Efficacy of Lansprazole 30mg BID Plus Usual Asthma Care vs. Placebo Plus Usual Asthma Care in Relieving Asthma Symptoms of Subjects With Asthma and Suspected GER	P.I., 1%	1999-2001
Merck	An Open Controlled Extension to the Chronic Asthma Study Comparing Montelukast with Placebo in 2-5 Year Old Patients	P.I., 1%	2000-2002
Merck	Effect of Montelukast vs. Placebo on Objectively Measured Nocturnal Cough in a Double-Blind, Randomized Trial of Children Ages 6-14 Years with Mild Asthma	P.I., 5%	2000-2002

GlaxoWellcome	A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via MDI and a Valved Holding Chamber with Facemask in Subjects With Asthma Age 6 Months to 23 Months	P.I., 1%	2000-2001
Pfizer	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-center Study of the Efficacy and Safety of Citirizine-Pseudoephedrine vs. Fexofenadine-pseudoephedrine vs. Placebo In the Treatment of Subjects Twelve years and Older with SAR	P.I., 10%	2000-2001
Procter and Gamble	Effects of Experimental Rhinovirus Infection on Immune Cell Profiles and Biomarkers of Pathogenesis	P.I., 10%	2000-2001
Schering-Plough	Effects of Desloratadine on Allergic Inflammatory Response Of the Nasal Mucosa Associated with Symptomatic SAR: A Nasal Biopsy Study	P.I., 1%	2000-2002
Genentech	An Observational Study of the Epidemiology and Natural History Of Asthma	P.I., 1%	2000-2003
Aventis	Effects of Long-Term Treatment of Intranasally Inhaled Triamunolone Acetonide in Children with Allergic Rhinitis	P.I., 1%	2001-2011
Astra-Zeneca	A Safety and Efficacy Study of Two Dosage-levels of Pulmicort Respules (Budesonide Inhalation Suspension, 0.5 or 1.0 mg/day) Versus Placebo in Infants Between the ages of Six and Twelve Months with Mild to Moderate Asthma		
Sepracor	An Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol and Placebo in Pediatric Subjects 2-5 Years Old with Asthma		
Aventis	A Phase III Multicenter, Double Blind, Placebo Controlled, Non Inferiority Study Assessing The Effects Of Ciclesonide Metered Dose Inhaler 50ug/Day And 200ug/Day (Ex-Valve) Administered Once Daily On Growth In Children With Mild Persistent Asthma		
Aventis	A Pilot Study to Characterize the Cytokine Immune Response to Immunization		
Viropharma	A Randomized, Double-blind, Placebo-Controlled Study to Evaluate The Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) in the Treatment of Viral Respirator Infection in Children 1 to 6 Years of Age		
Viropharma	A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Virologic Activity, and Safety of Pleconaril (Oral Suspension) In the Treatment of Viral Respiratory Infection in Children 7 to 12 Years of Age		
Astra-Zeneca	Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children between the Ages of One and Eight Years Treated with Pulmicort Respules versus Non-Steroidal Conventional Asthma Therapy		
Astra-Zeneca	"A Pilot Study to Evaluate the Effect of Nebulized Budesonide and Oral Corticosteroids on Asthma Relapse in Pediatric Patients Following Discharge from the Emergency Department/Outpatient Care Facility"	P.I., 4%	2003

Sepracor	"The Effect of Levalbuterol on Nasal Mucocilliary Clearance"	P.I., 15% 2003
Fetzer Institute	A stress Management Intervention for Children with Asthma	P.I, 5% 2003
Merck	"A Randomized, 2-Period, Multicenter, Double-Blind, Parallel-Group Study Comparing the Effects of 2 Doses of Montelukast Granules and Placebo in the Treatment of Respiratory Symptoms Associated with Respiratory Syncytial Virus-Induced Bronchiolitis in Children Aged to 18 Months"	P.I. 2003
Merck 2003	A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology during Natural Viral Upper Respiratory Infections	Co P.I. 11%
Novartis	An Investigation of the Safety and Efficacy of Elidel 1% Cream in Atopic Disease Modification, Assessed in a 3 Year Randomized Double Blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants and a 2-3 Year Open Label Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention with Elidel on the Incidence of Asthma in Children	
Merck	A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children	P.I. 15% 2004
Novartis	A One Year, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalizumab in Children (6-<12 Years) With Moderate-Severe, Persistent, Inadequately Controlled Allergic Asthma	
NIH/NIAD AI19262	Immune Mechanisms of Middle Ear Diseases	P.I. 30% 2003-2006
Heinz Foundation Wean Foundation HUD	The At Home Program	PI 2005
Greer Laboratories, Inc.	Parallel, Randomized, Double-Blind, Placebo Controlled Dose-Response Trial In Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis and Asthma Caused by Ragweed Pollen	PI 2006
Greer Laboratories, Inc.	Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Timothy Grass Pollen	PI 2006
Sanofi-Aventis	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study of the 12 Month Effect of Treatment with Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 micrograms) on the Growth Velocity of Children, 3 to 9 Years of Age, with Perennial Allergic Rhinitis PAR)	PI 2007
Adams Respiratory Therapeutics	A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo Controlled Study of the Safety and Efficacy of Mucinex D as Adjunct Therapy to Antibiotic Treatment of Acute Respiratory Infection	PI 2007

CURRENT RESEARCH INTERESTS

1. Relationships between respiratory viruses, asthma, immunity and stress.
2. Relationship between viral and allergen-induced nasal inflammation and middle ear disease.
3. Efficacy and safety of inhaled steroids on HPA axis function as measured by cosyntropin stimulation and growth utilizing stadiometry and knemometry to measure.
4. Use of a home-based telemetry unit to monitor cough in respiratory diseases.
5. Seasonal allergic rhinitis in children.
6. Mapping of common cold etiology in experimentally infected subjects.

7. Role of a sodium-potassium adenosine triphosphatase inhibitor in the control of secretion by mast cells and lymphocytes, and in allergic diseases.
-

SEMINARS AND INVITED LECTURES

1. The usefulness of an index to predict hospitalization of children with acute asthma. American Academy of Allergy and Clinical Immunology, March 1984, Chicago, IL.
2. The usefulness of an index to predict hospitalization of children with acute asthma. Pennsylvania Allergy Association, June 1984, Hershey, PA.
3. Eustachian tube obstruction (ETO) after provocative intranasal challenge with house dust mite. American Academy of Pediatrics, September 1984, Chicago, IL.
4. Histamine in middle ear fluids. American College of Allergists, February 1985, Bar Harbour, ME
5. Eustachian tube obstruction (ETO) after provocative intranasal challenge with house dust mite. American Academy of Allergy and Clinical Immunology, March 1985, New York
6. Histamine in middle ear fluids. XII International Congress of Allergology and Clinical Immunology, October 1985, Washington D.C.
7. Eustachian tube obstruction (ETO) after histamine nasal provocation - A double blind dose response study. American Academy of Allergy and Clinical Immunology, March 1986, New Orleans.
8. Seasonal fluctuations of middle ear histamine in otitis media with effusion (OME). Society for Pediatric Research, May 1986, Washington D.C.
9. Mucosal hyperresponsiveness: A mechanism for eustachian tube obstruction (ETO) in allergic rhinitis (AR). Society for Pediatric Research, May 1986, Washington D.C.
10. Plasma elevations of a prostaglandin (PG) F₂-alpha metabolite in acute asthma (AA). American Academy of Pediatrics, November 1, 1986, Washington, D.C.
11. Plasma elevations of a prostaglandin (PG) F₂alpha metabolite in acute asthma (AA). American Academy of Allergy and Clinical Immunology, February 1987, Washington, D.C.
12. Challenge Methods - Challenge Materials. Nasal Challenge Workshop, February 1987, Washington, D.C.
13. Plasma elevations of a prostaglandin (PG) metabolite in acute bronchiolitis (AB) and acute asthma (AA). ACRC Program Directors' Biennial Meeting, April 1987, Williamsburg.
14. Plasma histamine elevations in acute asthma (AA). Society for Pediatric Research, April 1987, Anaheim.
15. Plasma elevations of a prostaglandin (PG) metabolite in acute bronchiolitis (AB). Society for Pediatric Research, April 1987, Anaheim.
16. Intranasal challenge with histamine and saline - effects on tubal and nasal function. Fourth International Symposium on Recent Advances in Otitis Media, June 1987, Bal Harbour.
17. Inflammatory mediators in middle ear effusions. Fourth International Symposium on Recent Advances in Otitis Media, June 1987, Bal Harbour.
18. Plasma elevations of a prostaglandin (PG) metabolite in acute bronchiolitis (AB) and acute asthma (AA). Aspen Allergy Conference, July 1987, Aspen.
19. Nasal and bronchial challenge with allergens. International Symposium on Relationship between Nose and Bronchi, November, 1987, Ghent, Belgium.
20. Choice of provoking agents for non-specific nasal hyperresponsiveness. International Workshop on Nasal and Bronchial Challenge Tests, November, 1987, Ghent, Belgium.
21. Late phase eustachian tube (ET) and nasal allergic responses associated with inflammatory mediator (IM) elaboration. American Academy of Allergy and Clinical Immunology, March 1988, Anaheim.
22. Late phase nasal reactions. National Symposium on Nasal Function in Health and Disease, April 1988, Providence, Rhode Island.
23. Plasma elevations of histamine (HIST) and a prostaglandin (PG) metabolite in acute bronchiolitis (AB). Society for Pediatric Research, May 1988, Washington, D.C.
24. Inhibition of the sodium-potassium adenosine triphosphatase (Na,K ATPase) pump by plasma of allergic subjects. American Academy of Allergy and Clinical Immunology, February 1989, San Antonio.

25. Moderator, Nasal Provocation Seminar, American Academy of Allergy and Clinical Immunology, February 1989, San Antonio.
26. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, February 1989, San Antonio.
27. Defective function of the sodium potassium adenosine triphosphatase (Na,K ATPase) pump in allergy/asthma. Society for Pediatric Research, May 1989, Washington, D.C.
28. Intranasal challenge of cynomolgus monkeys with ascaris (ASC), ragweed (RW), bradykinin (BK) and histamine (HIST). International Symposium on Infection and Allergy of the Nose, June 1989, Baltimore.
29. Human response to intranasal challenge with bradykinin (BK), histamine (HIST), prostaglandin (PG) D2 and PGF2a. International Symposium on Infection and Allergy of the Nose, June 1989, Baltimore.
30. Airway Inflammation - Therapeutic Implications. Ontario Allergy Society, June 1989, Toronto.
31. Recent Advances in the Management of Lower Respiratory Allergy. ENT Centennial Celebration Symposium: ENT Diseases in Children, September 1989, Pittsburgh.
32. Pediatric Asthma. Pulmonary Physiology and Medicine Seminar, Sponsored by the Pennsylvania Society for Respiratory Care, September 1989, Pittsburgh.
33. Mediators in Middle Ear Fluid. Mid-West Allergy Forum, October 1989, Columbus.
34. Airway Inflammation - Therapeutic Implications. West Virginia University Family Practice Seminar, November 1989, Morgantown.
35. Asthma. Pediatric Grand Rounds, West Virginia University, January 1990, Morgantown.
36. Effect of chlorpheniramine (CHL) on airway physiology and symptoms during natural pollen exposure. Midwinter Meeting of the Association for Research in Otolaryngology, February 1990, St. Petersburg Beach FL.
37. Monkey model of allergic rhinitis. Schering-Plough Research, March 1990, Kenilworth.
38. Effect of chlorpheniramine (CHL) on airway physiology and symptoms during natural pollen exposure. American Academy of Allergy and Clinical Immunology, March 1990, Baltimore.
39. Moderator, Nasal Provocation Seminar, American Academy of Allergy and Clinical Immunology, March 1990, Baltimore.
40. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, March 1990, Baltimore.
41. Airway inflammation in asthma. Grand Rounds, Oakland Medical Center, April 1990, Oakland MD.
42. Bronchiolitis, Viruses and Asthma. Allergy and the Practitioner Course, Children's Hospital, April 1990, Pittsburgh.
43. Evolutions in the therapy of asthma. Pulmonary Grand Rounds, Mercy Hospital, May 1990, Pittsburgh.
44. Inhibition of the sodium-potassium adenosine triphosphatase (Na,K ATPase) pump in allergy/asthma. World Conference on Lung Health, May 1990, Boston.
45. Relationship of allergy to chronic middle ear disease in children. Asthma, Allergy, and Dermatology - Clinical Pearls and Basic Mechanisms, Colby College, July 1990, Waterville ME.
46. Inflammation in allergic rhinitis: therapeutic considerations. Glaxo Teleconference, August, September and October 1990, throughout United States.
47. Airway inflammation in allergy and asthma. Clinical Research Rounds, Children's Hospital, September 1990, Pittsburgh.
48. Evolutions in the therapy of asthma. Grand Rounds, Children's Hospital, September 1990, Detroit.
49. Airways inflammation in asthma - therapeutic implications. Current Therapy XXI, Scioto County Medical Society, October 1990, Portsmouth OH.
50. Evolutions in the therapy of asthma. Grand Rounds, Southside Hospital, October 1990, Youngstown OH.
51. Inflammatory mediators in reactive airway disease. Research Seminar, Magee Hospital, November 1990, Pittsburgh PA.
52. Evolutions in the therapy of asthma. Grand Rounds, Children's Hospital, November 1990, Akron OH.
53. Case Presentations on Asthma. Closed Workshop - "Evolving Treatment Strategies in Airway Disease Management", February 1991, New York, NY.
54. Evolutions in the therapy of asthma. Medicine Grand Rounds, St. Francis Medical Center, Feb, 1991, Pittsburgh, PA.
55. Effect of rhinovirus 39 infection on immune/inflammatory cell functions. American Academy of Allergy and Clinical Immunology, March 1991, San Francisco.
56. Moderator, Nasal Provocation Seminar, American Academy of Allergy and Clinical Immunology, March 1991, San Francisco.
57. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, March 1991,

- San Francisco.
58. Current considerations in the diagnosis and treatment of otitis media. Invited Participant, March 1991, Carlsbad, CA
 59. Airway inflammation in allergic rhinitis. Grand Rounds, St. Vincent Health Center, March 1991, Erie, PA.
 60. Evolutions in the therapy of asthma. Seminar for General Practitioners, March 1991, Butler PA.
 61. Evolutions in the therapy of asthma. Seminar for General Practitioners, March 1991, Pittsburgh PA.
 62. Evolutions in the therapy of asthma. Grand Rounds, Children's Hospital, April 1991, Dayton OH.
 63. Respiratory and allergic diseases. University of Pittsburgh School of Pharmacy 32nd Annual Spring Continuing Education Seminar on Respiratory and Allergic Diseases, April 1991, Pittsburgh PA.
 64. Evolutions in the treatment of airway disease. Southwest District, Pennsylvania Society of Respiratory Care, April 1991, Pittsburgh PA.
 65. Home-based telemetry objectively determines cough characteristics in children with asthma. Society for Pediatric Research, May 1991, New Orleans, LA.
 66. Use of home-based telemetry to objectively determine cough characteristics in children with asthma. American Lung Association, American Thoracic Society International Conference, May 1991, Anaheim, CA.
 67. Relationship between airway hyperreactivity (AHR) and sodium-potassium adenosine triphosphatase (Na,K ATPase) pump inhibition. American Lung Association, American Thoracic Society International Conference, May 1991, Anaheim, CA.
 68. The management of allergic rhinitis: Implications for upper and lower airways. Grand Rounds, Children's Hospital of New Jersey, May 1991, Newark, NJ.
 69. Treatment and control of seasonal allergic rhinitis. Seminar for General Practitioners, June 1991, Monongahela General Hospital, Monongahela, PA.
 70. Allergic Rhinitis. Grand Rounds, Weirton Medical Center, August 1991, Weirton, WV.
 71. Treatment and control of seasonal allergic rhinitis. Family Practice Seminar, West Virginia University School of Medicine, September 1991, Morgantown, WV.
 72. Pediatric Asthma. Allergy/Pulmonary Update 1991 - Park Nicollet Medical Center, October 1991, Minneapolis.
 73. Allergy and Ear Disease. Allergy/Pulmonary Update 1991 - Park Nicollet Medical Center, October 1991, Minneapolis.
 74. Evolutions in the therapy of asthma. Vermont Osteopathic Medical Association, October 1991, Burlington VT.
 75. Evolutions in the treatment of asthma. Seminar for General Practitioners, October 1991, Lower Speers PA.
 76. Evolutions in the treatment of asthma. Seminar for General Practitioners, October 1991, Burlington VT.
 77. Allergic Rhinitis. Allergy Grand Rounds, Children's Hospital, November 1991, Newark NJ.
 78. Management of Allergic Rhinitis. Butler County Medical Society, November 1991, Butler PA.
 79. NHLBI Guidelines and Their Effect on Treatment of Pediatric Asthma. Grand Rounds, Shenango Valley Hospital, November 1991, Farrell PA.
 80. Airway inflammation in allergic rhinitis: therapeutic implications. Seminar for General Practitioners, December 1991, West Palm Beach FL.
 81. Airway inflammation in allergic rhinitis: therapeutic implications. Seminar for General Practitioners, December 1991, Fort Lauderdale FL.
 82. Recent advances in the pathophysiology of primary immune deficiencies and immunoglobulin therapy in HIV infection and autoimmune/inflammatory neurological disorders. Invited Participant, January 1992, Indian Wells, CA.
 83. Advances in Asthma Care National Faculty Conference. Invited Participant, February 1992, Reston VA.
 84. Effect of seasonal ragweed (RW) exposure on the response to nasal ragweed challenge. American Academy of Allergy and Clinical Immunology, March 1992, Orlando FL.
 85. Moderator, Nasal Provocation Seminar, American Academy of Allergy and Clinical Immunology, March 1992, Orlando FL.
 86. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, March 1992, Orlando FL.
 87. Management of allergic rhinitis. Grand Rounds, Mercy Hospital, March 1992, Pittsburgh PA.
 88. Airway inflammation in allergic rhinitis. Grand Rounds, Robinson Memorial Hospital, March 1992, Ravenna OH.
 89. Airway inflammation in allergic rhinitis. Seminar for General Practitioners, Falls General Hospital, March 1992, Cuyahoga Falls, OH.
 90. Allergic rhinitis. Continuing Medical Education Program, Westmoreland Hospital, April 1992, Greensburg, PA.
 91. Allergic rhinitis - pathophysiology and treatment. Grand Rounds, Children's Hospital, April 1992, Pittsburgh PA.
 92. Asthma and allergic rhinitis. Grand Rounds, Doctor's Hospital, April 1992, Massillon OH.

93. Asthma and allergic rhinitis. Seminar for General Practitioners, April 1992, Canton OH.
94. The Clinical Implications of the NHLBI Guidelines by the Asthma Care Study Group for Primary Care Physicians. Invited Participant, April 1992, Washington DC.
95. Allergic rhinitis. Seminar for General Practitioners, April 1992, Windber PA.
96. Allergic rhinitis. Beaver County Medical Society Meeting, April 1992, Beaver PA.
97. Allergy testing: skin tests and RASTS vs. controversial procedures. Allergy for the Practitioner Symposium, Children's Hospital, April 1992, Pittsburgh PA.
98. Cases in Allergy Faculty. Invited Participant, May 1992, Tampa FL.
99. Allergic rhinitis (Joseph E. Ghory Memorial Lectureship). Ohio Society of Allergy and Immunology, May 1992, Columbus OH.
100. Allergic rhinitis. Seminar for General Practitioners, May 1992, Waynesburg PA.
101. Allergies. Invited guest, "Parent Talk", WQEX Television Studios, May 1992, Pittsburgh PA.
102. Allergic rhinitis. Grand Rounds, St. Elizabeth Hospital, May 1992, Youngstown OH.
103. Allergic rhinitis. Grand Rounds, Deaconess Hospital, May 1992, Cleveland OH.
104. Allergic rhinitis. Grand Rounds, Southside Hospital, June 1992, Youngstown OH.
105. Allergic rhinitis. Association of Philippine Physicians of Ohio, June 1992, Cleveland OH.
106. Allergic rhinitis. Grand Rounds, Conemaugh Valley Memorial Hospital, June 1992, Johnstown PA.
107. Allergic rhinitis. Seminar for General Practitioners, June 1992, Baton Rouge LA.
108. The management of allergic rhinitis. Grand Rounds, Baptist Hospital, August 1992, Pensacola FL.
109. Allergic rhinitis. Grand Rounds, Lutheran Hospital, August 1992, Fort Wayne IN.
110. Allergic rhinitis. Grand Rounds, Shadyside Hospital, August 1992, Pittsburgh PA.
111. Allergic rhinitis. Grand Rounds, McKeesport Hospital, August 1992, McKeesport PA.
112. Allergic rhinitis. Grand Rounds, Altman Hospital, September 1992, Canton OH.
113. Allergic rhinitis. Nurse Practitioner Conference, Carnegie Mellon University, September 1992, Pittsburgh PA.
114. Allergic rhinitis. Grand Rounds, St. Joseph's Hospital, September 1992, Loraine OH.
115. Complications of the Common Cold. Round Table Discussion, XIV Congress of European Rhinologic Society, October 1992, Rome Italy.
116. Asthma Update 1992. Asthma Educational Outreach Program, October 1992, Johnstown PA.
117. Allergic rhinitis in the elderly. Twelfth Annual Conference on Aging (Cambria-Somerset Council for Education of Health Professionals), October 1992, Seven Springs PA.
118. The NHLBI Guidelines for Diagnosis and Management of Asthma. Grand Rounds, Ohio Valley Hospital, October 1992, Wheeling WV.
119. The management of allergic rhinitis. Grand Rounds, Latrobe Hospital, November 1992, Latrobe PA.
120. The management of allergic rhinitis. Seminar for General Practitioners, November 1992, Toledo OH.
121. Allergic rhinitis and asthma. Grand Rounds, Conemaugh Valley Memorial Hospital, November 1992, Johnstown PA.
122. Recent advances in vaccine development and delivery, bone marrow transplantation and adhesion molecules in the immune response. Invited Participant, January 1993, Palm Beach FL.
123. The Management of Allergic Rhinitis. Grand Rounds, St. Mary's Hospital, January 1993, Milwaukee WI.
124. Acoustic Rhinometry. Rhinometry Workshop, January 1993, Tucson AZ.
125. Nasal and otologic effects of influenza A virus infection. Midwinter Meeting of the Association for Research in Otolaryngology, February 1993, St. Petersburg Beach FL.
126. Current modalities of asthma treatment. Grand Rounds, Somerset Medical Center, Feb., 1993, Somerset NJ.
127. Allergic rhinitis. Grand Rounds, Cabell Hospital, March 1993, Huntington WV.
128. Allergic rhinitis. Grand Rounds, General Hospital at Passaic, March 1993, Passaic NJ.
129. Allergic rhinitis. Update in Internal Medicine 1993 (Univ of Pittsburgh Med Center), March 1993, Pittsburgh PA.
130. Nasal Interleukin (IL) Levels During Experimental Influenza Virus Infection. American Academy of Allergy and Clinical Immunology, March 1993, Chicago IL.
131. Objective Measures of Nasal and Ear Function. Rhinitis/Sinusitis Course, American Academy of Allergy and Clinical Immunology, March 1993, Chicago IL.
132. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, March 1993, Chicago IL.
133. Airway Inflammation in Allergic rhinitis. Grand Rounds, Hamot Medical Center, March 1993, Erie PA.
134. The management of allergic rhinitis. Blue Grass Society for Asthma and Allergy, March 1993, Lexington Ky.
135. Allergic rhinitis - implications for the upper and lower airways. Seminar for General Practitioners, March 1993,

- Buffalo NY.
136. Allergic rhinitis. Grand Rounds, Mercy Hospital, March 1993, Johnstown PA.
 137. The Inflammatory Component of Asthma. Grand Rounds, St. Clares Hospital, April 1993, Denville NJ.
 138. Allergic rhinitis. Seminar for General Practitioners, April 1993, Rochester NY.
 139. Pharmacologic Management of Asthma. Sixth Biennial Pediatric Symposium (Children's Hospital Medical Center), April 1993, Cincinnati OH.
 140. Workshop on Office Management of Allergic Diseases. Sixth Biennial Pediatric Symposium (Children's Hospital Medical Center), April 1993, Cincinnati OH.
 141. Nasal and otologic effects of influenza A virus infections. Second Extraordinary International Symposium on Recent Advances in Otitis Media (with WJ Doyle, P Fireman, F Hayden and CA Buchman), April 1993, Oita Japan.
 142. Otitis Media (OM) as a Manifestation of Experimental Influenza A Virus Infection. Society for Pediatric Research Meeting, May 1993, Washington DC.
 143. The John H. Moyer Visiting Professor Lecture Series on Immune Deficiency and Allergy (Cambria-Somerset Council for Education of Health Professionals). Conemaugh Hospital, Lee Hospital, Memorial Hospital of Bedford County, Mercy Medical Center, Somerset Hospital, and Windber Hospital, May 1993, Johnstown PA.
 144. The management of allergic rhinitis. Seminar for Pharmacists, June 1993, Pittsburgh PA.
 145. Allergic rhinitis. Seminar for General Practitioners, June 1993, Pittsburgh PA.
 146. Emergency Treatment of Asthma in Pediatrics. Georgia Osteopathic Medical Association, June 1993, Amelia Island FL.
 147. Biochemical Mechanisms of Allergy and Airway Hyperreactivity. Pennsylvania Allergy Association 1993 Meeting, June 1993, Hershey PA.
 148. Allergic rhinitis. Seminar for General Practitioners, June 1993, Pittsburgh PA.
 149. The management of allergic rhinitis. Seminar for General Practitioners, August 1993, Aurora OH.
 150. The management of allergic rhinitis. Grand Rounds, Lutheran Hospital, August 1993, LaCrosse, WI.
 151. Inflammation in allergic rhinitis - therapeutic implications. Seminar for General Practitioners, August 1993, Albany, NY.
 152. The management of allergic rhinitis. Seminar for General Practitioners, September 1993, Detroit MI.
 153. The management of allergic rhinitis. Grand Rounds, Fairview General Hospital, October 1993, Cleveland OH.
 154. The management of allergic rhinitis. Seminar for General Practitioners, October 1993, Buffalo NY.
 155. The inflammatory component of asthma. Cleveland Allergy Society, October 1993, Cleveland OH.
 156. Management of seasonal allergic rhinitis in the 90's. Seminar for General Practitioners, October 1993, Cleveland OH.
 157. Biochemical Mechanisms of Allergy and Airway Hyperreactivity. Meeting of The Buffalo Allergy Society, October 1993, Buffalo NY.
 158. The NHLBI Guidelines for Diagnosis and Management of Asthma. Grand Rounds, Uniontown Hospital, October 1993, Uniontown PA.
 159. Allergy/Immunology Visiting Professor of the American Academy of Pediatrics, Hurley Medical Center and Michigan State University East Lansing Campus, November 1993, Flint and East Lansing MI.
 160. The Wheezing and Coughing Child. Pediatric Grand Rounds, Hurley Medical Center, November 1993, Flint MI.
 161. The Wheezing and Coughing Child. Grand Rounds, Michigan State University East Lansing Campus, November 1993, East Lansing MI.
 162. Airway Manifestations in Children with HIV. Otolaryngology Grand Rounds, UCLA Medical Center, December 1993, Los Angeles CA.
 163. Allergic rhinitis. Seminar for General Practitioners, December 1993, New Orleans LA.
 164. Effect of experimental rhinovirus 39 infection on the nasal response to histamine and cold air challenges in allergic and non-allergic subjects. Midwinter Meeting of the Association for Research in Otolaryngology, February 1994, St. Petersburg Beach FL.
 165. Allergic rhinitis. Baton Rouge Otolaryngology Society, February 1994, Baton Rouge LA.
 166. The management of allergic rhinitis: Implications of upper and lower airway disorders. Medical Potpourri Seminar of St. John West Shore Hospital, February 1994, Cleveland OH.
 167. Theophylline in the treatment of asthma. Closed Workshop on Controversies and Consensus in the Use of Theophylline for Childhood Asthma, February 1994, Denver CO.
 168. Update on allergic rhinitis. Grand Rounds, Baptist Hospital, March 1994, Kansas City MO.
 169. Extended release albuterol sulfate in children with bronchial asthma. American Academy of Allergy and Clinical Immunology, March 1994, Anaheim CA.

170. Moderator, Infections in Atopy and Asthma Seminar, American Academy of Allergy and Clinical Immunology, March 1994, Anaheim CA.
171. Moderator, Rhinomanometry Workshop, American Academy of Allergy and Clinical Immunology, Mar 1994, Anaheim CA.
172. Allergic rhinitis. Seminar for General Practitioners, March 1994, Canton OH.
173. Asthma: International report and medication update. Grand Rounds, Geisinger Medical Center, April 1994, Danville PA.
174. Allergic rhinitis. Grand Rounds, Licking Memorial Hospital, April 1994, Newark OH.
175. Management of allergic rhinitis. Seminar for General Practitioners, April 1994, Myrtle Beach SC.
176. The Role of Superantigens in Disease and Animal Models as Instructional Paradigms of Human Disease. Invited Participant, April 1994, Tucson AZ.
177. Otitis media - diagnosis and treatment. First Annual Allergy Fellows Symposium, May 1994, Boston MA.
178. Inflammatory component of asthma. Update on Asthma for the Practitioner Course (Memorial Hospital of Burlington County), May 1994, Mount Holly NJ.
179. Allergic rhinitis. Seminar for General Practitioners, June 1994, Medina OH.
180. Management of allergic rhinitis. Grand Rounds, Long Beach Memorial Medical Center, June 1994, Long Beach CA.
181. Management of allergic rhinitis. Grand Rounds, University of Tennessee, June 1994, Knoxville TN.
182. Allergic rhinitis and otitis media. Knoxville Otolaryngology Society, June 1994, Knoxville TN.
183. Allergic rhinitis. Grand Rounds, Warren General Hospital, August 1994, Warren OH.
184. Allergic rhinitis. Grand Rounds, Altman General Hospital, August 1994, Canton OH.
185. Allergic rhinitis. Family Practice Symposium, The Ed Bixby Institute for Postgraduate Medical Education, Research Medical Center, September 1994, Kansas City MO.
186. Respiratory virus infections in allergic patients. Wisconsin State Allergy Society, Sept., 1994, Madison WI.
187. Viral Infections and How They Relate to Asthma. Grand Rounds, All Children's Hospital, October 1994, St. Petersburg FL.
188. Asthma. Grand Rounds, Medical Center Hospital, November 1994, Marion OH.
189. Asthma. Managed Care Symposium, December 1994, Columbus OH.
190. Viral Infections and Asthma. Invited Discussant, Transatlantic Airway Conference, January 1995, Key Biscayne FL.
191. Allergic Rhinitis in Children Versus Adults - Pathophysiologic Similarities. Invited Discussant, Food & Drug Administration Workgroup, January 1995, Rockville MD.
192. Reproducibility of the effects of intranasal ragweed challenges in allergic subjects. Midwinter Meeting of the Association for Research in Otolaryngology, February 1995, St. Petersburg Beach FL.
193. Update on the NIH Guidelines for Diagnosis and Treatment of Asthma. County Medical Society Meeting, February 1995, Mansfield OH.
194. Moderator, Infections in Atopy and Asthma Seminar, American Academy of Allergy and Clinical Immunology, February 1995, New York NY.
195. Effect of influenza A virus (FLU) infection on cell-mediated immunity in allergic rhinitis (AR) and non-AR subjects. American Academy of Allergy and Clinical Immunology, February 1995, New York NY.
196. Respiratory Viral Infections and Asthma. Postgraduate Course Lecture, American Academy of Allergy and Clinical Immunology, February 1995, New York NY.
197. Inflammation in Asthma - Therapeutic Implications. Lake Erie College of Osteopathic Medicine Annual Meeting, March 1995, Clymer NY.
198. New Frontiers in the Immunoregulation of Allergic and Autoimmune Diseases. Invited Participant, March 1995, Phoenix AZ.
199. Update on Asthma. Community Mutual Insurance Company (CMIC) Managed Care Symposium, May 1995, Cincinnati OH.
200. Update on Asthma. Community Mutual Insurance Company (CMIC) Managed Care Symposium, May 1995, Dayton OH.
201. Otitis media - diagnosis and treatment. Second Annual Allergy Fellows Symposium, May 1995, Seattle WA.
202. Update on Asthma Management. Grand Rounds, Massillon Psychiatric Hospital, May 1995, Massillon OH.
203. Allergic Rhinitis Update. Seminar for General Practitioners, June 1995, Minneapolis MN.
204. Asthma - New Concepts and Treatment. 22nd Anniversary Refresher Course in Family Practice, University of Pittsburgh Medical Center, June 1995, Pittsburgh PA.
205. Update on Antihistamines for Allergic Rhinitis. Seminar for General Practitioners, June 1995, Minneapolis MN.
206. Comparison of the middle ear response to experimental infection with rhinovirus (RV)-39 and RV-Hanks.

- Midwinter Meeting of the Association for Research in Otolaryngology, February 1996, St. Petersburg Beach FL.
207. Moderator, Infections in Atopy and Asthma Seminar, American Academy of Allergy, Asthma and Clinical Immunology, March 1996, New Orleans LA.
208. Effect of experimental rhinovirus 39 (RV-39) infection on nasal bradykinin (BK) levels. American Academy of Allergy, Asthma and Clinical Immunology, March 1996, New Orleans LA.
209. Allergic Rhinitis. National Association of Pharmacists. January 1997.
210. Diminished IL-10 production. Association for Research in Otolaryngology. February 20, 1997. San Francisco, CA
211. National Allergy Fellows Symposium. May 1996, San Francisco, CA
212. American Academy of Allergy, Asthma and Immunology. Moderator, Viral/Allergen Interactions in the Airways. Symposium.
213. American Academy of Allergy, Asthma and Immunology. Moderator, Atopy and Viral Infections. Symposium.
214. National Asthma Consultants Meeting. Systemic side effects of Inhaled Corticosteroids. October 1996.
215. Grand Rounds. Morton Plant Hospital. Tampa, FL. March 4, 1997. Allergic Rhinitis. New Approaches for the Diagnosis and Management of Asthma. March 11, 1998. Louisville, KY
216. Profile for American Academy of Allergy, Asthma and Immunology News. March 25, 1998
217. Innovative Strategies for Immune Therapeutics. March 26-29, 1998. Bodega Bay, CA
218. New Approaches for the Diagnosis and Management of Asthma. April 2, 1998. Grand Rapids, MI
219. New Approaches for the Diagnosis and Management of Asthma. April 9, 1998. Ft. Myers, FL
220. New Approaches for the Diagnosis and Management of Asthma. April 22, 1998. Williamsville, NY
221. New Approaches for the Diagnosis and Management of Asthma. April 24, 1998. Callicoon, NY
222. E11-Clear Communication: The Critical Step for a Smooth Transition From CFC to HFA Formulations. Measuring and Assessing Efficacy of the Transition to the New Formulations. April 24-29, 1998. Chicago, IL
223. New Approaches for the Diagnosis and Management of Asthma. April 28, 1998. Chicago, IL
224. New Approaches for the Diagnosis and Management of Asthma. April 29, 1998. Kalamazoo, MI
225. New Approaches for the Diagnosis and Management of Asthma. April 29, 1998. Lemont, IL
226. 14th Annual Clinical Virology Symposium. April 26-29, 1998. Clearwater Beach, FL
227. New Approaches for the Diagnosis and Management of Asthma. April 30, 1998. Milwaukee, WI
228. Azmacort Speakers Training. May 1-3, 1998. Orlando, FL
229. The American Pediatrics Society/The Society for Pediatric Research poster session presentation. May 4, 1998. New Orleans, LA
230. Allergy and Immunology In Training Examination. May 4, 1998.
231. New Approaches for the Diagnosis and Management of Asthma. May 7, 1998. Fort Wayne, IN
232. New Approaches for the Diagnosis and Management of Asthma. Pulmicort Turbohaler. May 9, 1998. Chicago, IL
233. Asthma Management 1998. Asthma and the Use of Singulair. Einstein Medical Center, NY
234. Leukotrienes in Asthma. May 14, 1998. Pittsburgh, PA
235. New Approaches for the Diagnosis and Management of Asthma. Pharmacotherapy. May 14, 1998. San Antonio, TX
236. Current Perceptions in about the Treatment of Seasonal Allergic Rhinitis and Chronic Urticaria. May 14-17, 1998. Boca Raton, FL
237. New Approaches for the Diagnosis and Management of Asthma. May 19, 1998. Louisville, KY
238. New Approaches for the Diagnosis and Management of Asthma. May 21, 1998. Bay City, MI
239. New Approaches for the Diagnosis and Management of Asthma. May 26, 1998. Port Charlotte, FL
240. New Approaches for the Diagnosis and Management of Asthma. May 27, 1998. Joplin, MO
241. New Approaches for the Diagnosis and Management of Asthma. May 30, 1998. Addison, IL.
242. New Approaches for the Diagnosis and Management of Asthma. Pharmacotherapy and Patient Education. June 3, 1998. Charlottesville, VA
243. Livostin Advisory Board Meeting. Approach to Managing Allergy Patients. June 4, 1998. Washington D.C.
244. Asthma and Allergy Utilizing Pharmacogenetics and Cost-Effective Approaches for Target Validation. June 4-5, 1998. Baltimore, MD
245. New Approaches for the Diagnosis and Management of Asthma. June 5-6, 1998. Columbus, OH
246. New Approaches for the Diagnosis and Management of Asthma. June 7, 1998. Pittsburgh, PA
247. Asthma Management in the School Setting. August 14, 1998. Pittsburgh, PA.
248. Effect of Rhinovirus in Asthma. American Academy of Allergy, Asthma and Immunology. March 3, 1999. Orlando, FL
249. Pharmacological Treatment of Allergic Rhinitis. American Academy Allergy, Asthma and Immunology. March 2,

1999. Orlando, FL
250. Viral Infections Inducing Airway Inflammation. Co-Moderator. American Academy Allergy, Asthma and Immunology. February 28, 1999. Orlando, FL.
251. Grand Rounds - Regions Hospital, August 6, 1999, St. Paul MN
252. St. Joseph's Hospital, Grand Rounds, August 19, 1999, Parkersburg, WV
253. Pediatric Respiratory Consultants Meeting, August 27, 1999, Seattle, WA
254. National Meeting, September 21, 1999, Puerto Rico
255. St Francis Hospital Grand Rounds - September 24, 1999, Pittsburgh, PA
256. Frick Hospital Grand Rounds, September 28, 1999, Mt. Pleasant, PA
257. 3 Rivers Pediatric Update, October 23, 1999, Pittsburgh, PA
258. Westmoreland Hospital Grand Rounds, November 5, 1999, Greensburg, PA
259. "Asthma in the Year 2000 and Beyond". January 21-23, 2000, Bergamo, Italy
260. Visiting Consultantship, January 27, 2000, Johnstown, PA
261. "The Role of Leukotrienes in Asthma". February 12, 2000, Latrobe Hospital, Latrobe, PA Grand Rounds
262. "Managing Pediatric Asthma in the New Millennium". February 23, 2000, MSD Symposium, Nice, France
263. American Academy of Allergy Asthma and Immunology. San Diego, CA, March 3, 2000
264. "An Overview of Outcomes Management, March 9, 2000, Children's Hospital of Pittsburgh, Pittsburgh, PA.
265. Grand Rounds, Lancaster General Hospital. March 11, 2000, Lancaster, PA
266. Grand Rounds. "Use of Controller Medications for Pediatric Asthma". March 14, 2000, Mercy Hospital of Pittsburgh, Pittsburgh, PA.
267. 22nd Annual Symposium Kentucky Society for Allergy & Asthma & Immunology, "Management of Allergic Diseases in the New Millennium". April 14-16, 2000, St. Joseph Hospital. Lexington, KY.
268. Pediatric Teaching Day. Nassau County Medical Center. "Allergic Drug Reactions", and "Management of the Acute Asthmatic Attack". April 13, 2000, Garden City, NY.
269. Pediatric Academic Society Meeting/American Academy of Pediatrics. May 12-16, 2000, Boston, MA.
270. American Association of Physicians of Indian Origin. June 29, July 2, 2000, NY Marriott Marquis Hotel.
271. Pediatric Asthma Colloquia. Columbus Children's Hospital. August 2, 2000, Columbus, OH.
272. Visiting Professorship, Walter Reed Hospital - "Honey I Shrunk the Kids", August 17, 2000, Washington, DC.
273. VA Chapter of AAP - "Inhaled Steroids in Allergy Management, Bone Growth and Alternative Management," September 22, 2000
274. "New Anti-inflammatory Therapy for Children with Asthma," - October 11, 2000, Pittsburgh, PA
275. "Dental and Facial Abnormalities in Children with Allergic Rhinitis," - October 13, 2000, Mystic, CT
276. XVII International Congress of Allergology and Clinical Immunology - October 15-20, 2000 - Sydney, Australia
277. ACAAI - "How Practice Parameters Can Tame Managed Care," - November 7, 2000 - Seattle, WA
278. "Inhaled Steroids in Children," - November 11, 2000 - Johns Hopkins, Baltimore, MD
279. Combined Eastern Allergy Conference - January 11-13, 2001, Acapulco, Mexico
280. WSAAI 39th Annual SCIE Session - January 21-25, 2001, Hawaii
281. Grand Rounds - "Flonase," - February 22, 2001, Beaver Medical Center
282. AAAAI Conference - "Novel Approaches to Home Management of Acute Asthma," March 16-20, 2001, New Orleans, LA
283. Three Rivers Clinical Pediatric Update - "Controller Medications for Asthma," - March 29-31, 2001, Pittsburgh, PA
284. "Treatment of Asthma in Young Children" - April 19, 2001, Philadelphia, PA
285. "Asthma Medications - Part II" and "Serious Otitis Media and it's Relationship to Asthma," - April 21, 2001, Vestal, NY
286. Allergy Educators' Summit: Bone Growth Suppression" - April 27-29, 2001, Greenbriar, WV.
287. Medical Grand Rounds - "Management of Allergies," - May 1, 2001, UPMC McKeesport
288. 4th Annual Workshops in Rhinosinusitis - May 5-6, 2001, Whistler, BC
289. "Update on Allergic Rhinitis and Related Disorders," - May 7, 2001, Bethesda, MD
290. Pediatric Grand Rounds - May 11, 2001, Allegheny General Hospital
291. Medical Grand Rounds - "Allergic Rhinitis," - June 6, 2001, St. Francis Medical Center, Pittsburgh, PA
292. International Leukotriene Symposium: "Role of Leukotriene Receptor Antagonists in the Management of Childhood Asthma" - June 22-26, 2001, Tokyo, Japan
293. 21st Symposium Ear, Nose & Throat Diseases in Children 2001 Update, July 20-21, 2001, Pittsburgh, PA

294. Pediatric Grand Rounds. Children's Hospital of Pittsburgh. September 6, 2001, Pittsburgh, PA
295. Pediatric Grand Rounds. Children's Hospital of Buffalo. July 6, 2001, Buffalo, NY
296. Pediatric Asthma in the New Millenium Symposium: "Inhaled Corticosteroids: New Agents, Risks and Benefits" – September 22, 2001, New Brunswick, NY.
297. Allergy and Imperatives Regional Speakers' Training Meeting: "Perspectives in the Burden of Allergic Disease" and "Systemic Safety of Nasal Steroids" – October 5-7, 2001, New York, NY.
298. Focus 2001 – St. Vincent Health Center: "Pediatric Asthma" – October 19, 2001, Erie, PA.
299. Mid Atlantic Conference of Lead Safe Housing and Healthy Homes: "Illnesses Caused by Unhealthy Conditions" – October 28-30, 2001, Pittsburgh, PA.
300. American College of Chest Physicians: Viral Infections and Asthma: New Cellular and Molecular Links" – November 6, 2001, Philadelphia, PA.
301. ACAAI: Moderator – "New Clinical Correlates Influencing Asthma and Rhinitis Therapy" – Speaker – "Safety Alert: Inhaled Corticosteroids" – November 16, 2001, Orlando FL.
302. ICAAC: "Virus Induced Reactive Airway Disease: The Role of Inflammatory Cytokines" – December 27, 2001, Chicago, IL.
303. AAAAI Conference – "Interaction Between Infectious Agents and Atopic Disease" – March 1-6, 2002 – New York, NY.
304. Scientific Day – "Reactive Airway" – The Washington Hospital – May 3, 2002 – Southpointe, PA.
305. AAAAI Conference – Workshop: "The Atopic March: Development of Respiratory Disease in Infants with Atopic Dermatitis": Development of Rhinitis – March 7-12, 2003 – Denver, CO.
306. AAAAI Conference – Symposium- "Evolving Concepts in the Treatment of Asthma: Key Insights into Current and Future Therapies – "ICS: Safety Issues in the Book Ends of Life" – March 7-12, 2003 – Denver, CO.
307. AAAAI Conference – Seminar: Discussion Leader – "Recognition and Management of Osteoporosis in Asthmatics" – March 7-12, 2003 – Denver, CO.
308. Medical Ground Rounds, -"The Allergy/Asthma Linkage"-April 23, 2003, Allegheny General Hospital, Pittsburgh, PA.
309. Research Seminar Series, Center for Genomic Sciences,-"Nasal Versus Systemic Corticosteroids for Allergic Rhinitis in Children"-April 28, 2003, Allegheny General Hospital, Pittsburgh, PA.
310. Allergy and Asthma Grand Rounds,-"Update on Epidemiology of Asthma in Pittsburgh"-May 5, 2003, Allegheny General Hospital, Pittsburgh, PA.
311. The Pittsburgh Spring Asthma and Allergy Update-CME Conference: Conference Director- "Epidemiology of Asthma in the Pittsburgh Region"; " Safety and Efficacy of Asthma Controllers"; "Treatment of the Nose in Allergy/Asthma" (workshop) - May 29, 2003- Allegheny General Hospital, Pittsburgh, PA.
312. Pediatric Teaching Day: Lecturer- "The Asthma Spotlight on Pre-Schoolers!"- June 16, 2003, Forbes Regional Hospital, Monroeville, PA.
313. National Pediatric Asthma Congress-MSD Satellite Symposium: Lecturer-"The Use of Controller Mediations in Childhood Asthma and Viral Wheeze"-September 3, 2003, JiaXing, China.
314. Western Pennsylvania Conference on Asthma: Conference Director /Lecturer- "Asthma Facts and Figures-The Nation and Western Pennsylvania"; Panel Discussion: "Rescue Versus Controller Medications: How Do Physicians Change the Way They Treat Asthma? - September 20, 2003, Pittsburgh Marriott North, Cranberry Township, PA.
315. CHEST 2003: Moderator:-"Managing Exacerbations in Asthma and COPD"- Lecturer: "Causal Factors in Exacerbations"- October 27, 2003, Gaylord Palms, Orlando, Florida.
316. ACAAI 2003 Annual Meeting: Lecturer-"Natural History of Pediatric Asthma & Atopy"; Pediatric and Rhinitis/Sinusitis Committees Member; November 7-12, 2003, New Orleans, Louisiana.
317. St. John's University Third Annual Asthma Symposium/Current Trends and Advances in Asthma: Lecturer-"The Link between the Upper and Lower Airways"-November 13, 2003, St. John's University, Jamaica, New York.
318. AAAAI Annual Meeting: Moderator-"Practical Considerations in the Use of Corticosteroids for Allergic Rhinitis/Asthma: What Should I Do and Say"; Symposium-"ICS and Safety: Effects of Dose and Drugs"; Moderator- "Efficacy and Controversies in the Use of Intranasal and Inhaled Steroids"; Speaker-"Has the Move Towards Newer Corticosteroids Completely Freed Us form the Possibility of Growth Suppression in Children? Lung vs Nose Considerations"-March 19-23, 2004, San Francisco, CA.
319. Fifth Malaysian Congress of Allergy and Immunology (FMCAI): Lecturer-"Dental and Facial Abnormalities in Children with Allergic Rhinitis"; "The Role of Leukotriene Receptor Antagonist in the United Airway Disease"-

- April 2-4, 2004, Nikko Hotel Kuala Lumpur, Malaysia.
320. Western Pennsylvania CME Conference on Asthma: Conference Director /Lecturer: "The Atopic March"-April 24, 2004, Pittsburgh, Pennsylvania.
321. Beaver County Medical Society: Lecturer: "Update on Pediatric Asthma"-May 13, 2004, Beaver, Pennsylvania.
322. AR Pri-Med Update: Lecturer: "Allergic Rhinitis: Effective Treatment for Optimal Outcomes"-June 10, 2004, Hartford, Connecticut.
323. Florida Pediatric Society/Florida Chapter of the American Academy of Pediatrics: General Pediatric Update X Annual Meeting: Lecturer-"Asthma"-June 20, 2004, Boca Raton, Florida.
324. National Meeting of the Venezuelan Society of Allergy, Asthma & Immunology: Lecturer: Topic: Asthma Treatment- June 23-June 24, 2004, Margarita Hilton, Venezuela.
325. 2004 Allergist Advisory Board Meeting (Aventis): Consultant-August 5- 8, 2004, The American Club, Kohler, Wisconsin.
326. Pennsylvania Department of Health/Asthma Summit: Lecturer: Topic: Reaching Healthy People 2010 Goals-August 10, 2004, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
327. "Pediatrics-Head to Toe": Lecturer Faculty Member: Topic: Exercise-Induced Bronchospasm-October 9, 2004, Allegheny General Hospital, Pittsburgh, PA.
328. AAP Symposium: Lecturer: Topic: "Early Intervention and Prevention Strategies for Optimal Outcomes for Pediatric Asthma Patients"-October 9, 2004, San Francisco, California.
329. ACAAI 2004 Annual Meeting: Rhinitis/Sinusitis Committee/Presenter: "Aerobiology, Allergens, Allergen Extracts/Pharmacology" (November 15, 2004), November 12-17, 2004, Boston, MA.
330. TPAIS Conference: Speaker/Panel Discussion & Lecturer-"Viruses and Asthma", November 19-23, 2004, Mumbai, India.
331. Transatlantic Airway Conference (TAC 2005): Discussant, January 19 to 21, 2005, Key Biscayne, FL.
332. National Faculty Preparation Meeting 2005: Participant; January 21-22, 2005, Dallas, TX.
333. Central Florida Allergy Society, Lecturer: Topic: Asthma; January 27 to 28, 2005, Orlando, FL
334. Miami Children's Hospital 40th Annual Pediatric Postgraduate Course: "Perspectives in Pediatrics": Lecturer: "Allergies and Ear Infections", January 28-February 3, 2005 (January 31, 2005), Miami, FL.
335. Pittsburgh Allergy Society, Lecturer: Topic: Strategies for improving local asthma management; March 8, 2005; Pittsburgh PA.
336. Treatment & Management of Asthma: CME Faculty Development Program: Participant, March 11- 13, 2005; Miami, FL.
337. 2005 AR-Pri-Med Update: "Treating Allergic Rhinitis: Mechanism-based Evaluation and Treatment Strategies", March 22, 2005, Detroit, MI.
338. Pediatric Advisory Board Meeting: Participant, May 2-3, 2005, New York, N.Y.
339. Central Florida Pediatric Society, Lecturer, Topic: Asthma; May 11, 2005, Orlando, FL.
340. Clinical Expert Forum (Schering-Plough): Participant; May 13, 2005, Houston, TX.
341. Rhinitis Multi-Disciplinary Advisory Board (Sanofi-Aventis): Participant; June 6-7, 2005, Dallas, TX.
342. Third Annual Western Pennsylvania CME Conference on Asthma: Moderator/Lecturer; "Controller Therapy in Asthma-When to Start, What to Use, How Long to Continue"; June 8, 2005, Pittsburgh, PA.
343. City Symposia: Lecturer; August 8-11, 2005, Beijing, Shanghai, and Guangzhou, China.
344. National Allergist Advisory Board Meeting: Participant; August 11-14, 2005, La Jolla, CA.
345. Adams Panel Meeting: Participant; August 25-26, 2005, Short Hills, NJ.
346. Pediatric Roundtable: "Pediatric Challenges in Allergy: Redefining the Role of Antihistamines: Participant; September 14, 2005, Boston, MA.
347. Pediatric Respiratory Advisory Board Meeting: Lecturer; "A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology During Natural Viral Upper Respiratory Infections"; September 15-16, 2005, Chicago, IL.
348. Pediatric Head to Toe: Lecturer: "Asthma & School Sports: What's New?" September 17, 2005, Pittsburgh, PA.
349. Respiratory Specialty and Hospital Representatives Meeting: Lecturer; September 29, 2005, Los Angeles, CA.
350. 2005 American Academy of Pediatrics National Conference (Symposium): Lecturer: "Deciphering the Clues: Detailing the Environment, Comorbid, and Lifestyle Factors that Influence the Course of Pediatric Asthma"; October 8, 2005, Washington, DC.
351. Grand Rounds, St. Luke's Hospital: Lecturer: "Current Trends in Asthma Treatment"; October 25, 2005, Bethlehem, PA.
352. CHEST 2005: Panel Discussion/Participant: "Early Intervention and Prevention Strategies for Optimal Outcomes in Pediatric Asthma Patients"; October 31, 2005, Montreal, Canada.

353. Advisory Board Meeting: Participant: "Optimizing Key Opinion Leader Investigators in Clinical Trials"; November 4, 2005, East Hanover, NJ.
354. Elidel Speaker Update: Participant; January 27-28, 2006, Marco Island, FL.
355. Advances in 5-Lipoxygenase Science Advisory Board Meeting: Participant; February 2-4, 2006 Henderson, NV.
366. Core Asthma Group Advisory Board Meeting: Participant; February 10-11, 2006, Phoenix, AZ.
367. Advisory Board Meeting: Participant; March 1-2, 2006, Miami FL.
368. AAAAI 2006 Annual Meeting: Participant (posters); March 3-7, 2006, Miami, FL.
369. 2nd Asian Pediatric MetaForum: Expert panel; April 8, 2006, Hong Kong Academy of Medicine, Hong Kong.
370. Latin American Speakers' Forum; Inflammation in the Human Airway: Biology, Diagnosis and Treatment: Participant/Lecturer: "The Approach to the Management of Asthma in Kids"; April 28-29, 2006, Sao Paulo, Brazil.
371. Washington Hospital Scientific Day Conference; Lecturer: "Pediatric Asthma", May 12, 2006, Southpointe, PA.
372. Pediatric Grand Rounds: University of Massachusetts Medical School; Lecturer: Topic: Otitis Media; May 19, 2006, Worcester, MA.
373. National Respiratory Experts Forum; Participant; June 15-17, 2006, Chicago, IL.
374. CIPP VII 7th International Congress on Pediatric Pulmonology: Poster presentation; July 8-11, 2006, Montreal Canada.
375. Pediatric Respiratory Advisory Board Meeting: Participant, August 3-5, 2006, Denver, CO.
376. Taiwan Pediatric Allergic Society: Lecturer :Topic: The Management of Young Wheezy Kids, August 21, 2006 Taichung, Taiwan.
377. European Respiratory Society (ERS) Annual Congress 2006: Poster presentation; September 2-6, 2006, Munich, Germany.
378. Asthma Stakeholder Meeting: Participant; October 4, 2006, Harrisburg, PA.
379. XVIII World Congress of Asthma-Interasma: Participant; October 13-17, 2006, Guadalajara, Jalisco, Mexico.
380. MSD Europe, Middle East and Africa (EMEA) Pediatric Speakers' Forum: Chairman & Speaker: Topic: The Spectrum of Childhood Asthma: A Call for More Treatment Options; Lecture: Different Kids-Different Needs; October 19-21, 2006, Prague, Czech Republic.
381. Nemaolin Asthma Conference: Moderator & Speaker: Inhaled Corticosteroids/Leukotriene Receptor Antagonists Safety and Efficacy, Including Airway Restructuring; November 4-5, 2006, Nemaolin Woodlands Conference Center, Farmington, PA.
382. Allergy, Asthma & Immunology Annual Scientific Meeting (ACAAI): Poster Presentations; November 9-15, 2006, Philadelphia, PA.
383. NICHD/NIAD Editorial Roundtable: Pediatric Asthma: Today's Management-Tomorrow's Potential: Lecturer: Adverse Events: The Current and Evolving Understanding of ICS and Growth Suppression; December 7- 8, 2006; Bethesda, MD.
384. Pediatric Respiratory Advisory Board Meeting: Participant; December 9, 2006; Dallas, TX.
385. MFF Advisory Board Meeting: Participant; December 15, 2006; Miami, FL.
386. Pre-Conference Symposium/Combined Meeting on Allergy, Asthma & Immunology: Lecturer; January 17-18, 2007; Puerto Vallarta, Mexico.
387. 2007 Respiratory Speakers Forum for Asthma: Participant; January 19-21, 2007; Atlanta, GA.
388. Pediatric Trial Design Meeting: Participant; January 26, 2007; Ft. Worth, Texas.
389. AAAAI 2007 Annual Meeting: Participant (posters/oral abstract); February 23-27, 2007; San Diego, CA.
390. Latin America Speakers' Forum: Chairman/Lecturer; March 8-10, 2007; Cartagena, Columbia.
391. DGP Kongress Symposium: Speaker; March 14-16, 2007; Mannheim, Germany.
392. 2007 National Allergist Advisory Board Meeting: Participant; March 16-18, 2007; Phoenix, AZ.
393. Asia Pacific Pediatric Speakers' Forum: Lecturer; March 23-25, 2007; Seoul, South Korea.
394. Multidisciplinary Advisory Board Meeting: Participant; June 15-16, 2007; Dallas, TX.
395. PAAA 2007 Annual Meeting: Lecturer; "Role of Viral URI's in the pathogenesis of upper airway disease"; "Safety and efficacy of controller therapies for asthma"; June 22-24, 2007; Hershey, PA.
396. International Pediatric Symposium; (Lecturer); June 26-27, 2007; Romania.
397. Pediatric Respiratory Advisory Board Meeting: Participant; July 12-14, 2007; Chicago, IL.
398. Symposium & Advisory Board Meeting: Participant, August 9-10, 2007; San Diego, CA.
399. Infant Wheezing Course: Universidade Federal de Sao Paulo: Lecturer; September 7, 2007; Sao Paulo, Brazil.
400. Nemaolin Asthma Conference: Program Director/Speaker: Safety and efficacy of Asthma therapeutics in the context of the new NAEPP guidelines; September 14-16, 2007, Nemaolin Woodlands Conference Center, Farmington, PA.
401. Advances in Respiratory Therapeutics Forum (ART FORUM): Speaker: Ciclesonide in the treatment of asthma-A focus on safety; October 5-7, 2007, Athens, Greece.
402. Pediatric Advisory Board Meeting: Participant, October 12-13, 2007; Washington, DC.
403. Scientific & Leadership Academy: Participant/Lecturer; October 18, 2007; Philadelphia, PA.

- 404. University of Pittsburgh Graduate School of Public Health: Capstone Course: Problem Solving in Public Health: Asthma: Lecturer; October 22, 2007; Pittsburgh, PA.
 - 405. American College of Chest Physicians (CHEST) Annual Meeting: Poster presentation; October 20-25, 2007; Chicago, IL.
 - 406. Speaker Lecture Series: Lecturer; Topic: EACCI/AAAAI Pediatric Guidelines; October 26-30, 2007; Jeddah, Saudi Arabia.
 - 407. American College of Asthma, Allergy & Immunology (ACAAI): Poster presentations; November 9-14, 2007; Dallas, TX.
 - 408. Allergic Rhinitis Expert Meeting: Participant: December 17, 2007; Paris, France.
 - 409. ICS Growth Roundtable: Participant: January 11-12, 2008, Dallas, TX.
 - 410. Gulf Scientific Lecture Program: Lecturer; January 21-24, 2008; United Arab Emirates.
 - 411. Asthma Specialists Asthma Advisory Board Meeting: Participant; January 31-February 1, 2008; Braselton, GA.
-

COMMUNITY SERVICE

UNIVERSITY AND MEDICAL SCHOOL

Animal Research and Care Committee	Children's Hospital
Clinical Laboratory Use Committee	Children's Hospital
Human Rights Committee	Children's Hospital
Resident Education Committee	Children's Hospital
General Clinical Research Center	Children's Hospital
Committee to Fund Interest Section Research Projects	American Academy of Allergy and Immunology
Chairman, Rhinitis Committee	American Academy of Allergy and Immunology

COMMUNITY ACTIVITIES

Active staff	Allegheny General Hospital
--------------	----------------------------

CONTINUING MEDICAL EDUCATION (CME) ACTIVITIES

Attend annual meetings of the American Academy of Allergy and Immunology and the Society for Pediatric Research.
Participate in CME activities offered by other institutions and learning groups.